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Major Director: Da-ren Chen, Ph.D., Professor and Floyd D. Gottwald, Sr. Chair,  
Department of Mechanical and Nuclear Engineering 
 
The Electrospray (ES) technique is a promising particle generation method for drug delivery due  
to its capabilities of producing monodisperse PLGA composite particles with unique 
configurations and high drug encapsulation efficiency. In the dissertation work, the coaxial dual 
capillary ES was used to generate drug-loaded core-shell PLGA particles to study the effects of 
particle filling materials, drug loading locations and particle shell thicknesses on the resultant in 
vitro release behaviors of the hydrophilic and/ or hydrophobic model drugs. The work can be 
divided into two parts: 1) the extended release of the combination of a highly hydrophilic 
compound (Theophylline, THY) and a highly hydrophobic compound (Budesonide, BUD) and 2) 
the extended and sequential release of the combination of a hydrophilic large-molecule 
compound (Bovine Serum Albumin, BSA) and a hydrophobic small-molecule compound 
(Paclitaxel, PTX). In the part 1 research work, the coaxial dual capillary ES was employed to 
generate core-shell PLGA particles (particle size: 400 nm and 1 μm) loaded with THY and/ or 
BUD to study the critical factors for extended release of both drugs. The results suggest that the 
PLGA with a lower molecular weight is suitable for slowing down the release rate of THY due 
 
 
xvii 
to its lower porosity. The particle shell thickness is also essential to further decrease the release 
rate of THY, and co-encapsulation of BUD and THY in the particle core was confirmed to be the 
most effective drug loading strategy for extended release of both drugs. In the part 2 research 
work, PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 50/50) was selected as the particle filling 
material. Release rate of BSA could be decreased by increased particles shell layer thicknesses. 
The sequential release of BSA and PTX was achieved with 400-nm PLGA particles by loading 
the two drugs together in the particle core because the BSA release rate was accelerated by the 
presence of PTX in the particle core. The formulation strategy obtained in this study can be in 
principle generalized for biopharmaceutical applications of extended release and sequential 
release in fixed-dose combination therapy.  
 1 
 
 
 
 
 
 
 
Chapter 1 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
1.1 Significance of Extended Release Drug Delivery Systems  
     Surgery, psychotherapy, physical therapy, radiation, and pharmacotherapy are 
methods usually used to treat illnesses and diseases clinically. Among them, 
pharmacotherapy (treatment with drugs) is the most frequently used technique 
because it is, generally speaking, the most cost-effective and preferred method with 
the broadest range of applications to the greatest variety of disease states. With the 
advancement of modern pharmaceutical technology, pharmacotherapy can even be 
considered as the first line therapy against certain diseases that were conventionally 
treated by other forms of treatment. 
     Over the past 120 years, health regulations and amendments have been 
promulgated by the government of the United States of America to control quality, 
safety and efficacy of drugs/ products and to ensure that they undergo strict review 
and approval processes before listed into the market. The IND (Investigational New 
Drug) application and review were also included into the pharmaceutical product 
development process to further assure adequate protection for subjects recruited into 
human clinical trials [Banker and Rhodes, 2002]. However, there is still room for 
further improvement to provide patients with better life quality when administrated 
with pharmacotherapy.  
     Figure 1.1 is a typical pharmacokinetic level-time curve of a non-intravenous 
systemic drug delivery system describing the relationship between the concentration 
of the active pharmaceutical ingredient of a drug product in the plasma and the time 
after it is administered to a patient. The therapeutic window denoted in Figure 1.1 (A) 
represents the range of the plasma drug concentration when the drug product 
 3 
administered is efficacious but non-toxic to the patient during its duration. Figure 1.1 
(B) shows the real situation of the multiple dose treatment that the dose accumulation 
phenomenon is usually seen after the same drug product is repeatedly administered to 
a patient. The dose accumulation could impose a risk that allows the drug plasma 
concentration to exceed the level of minimum toxic concentration (MTC) and to bring 
toxicity and side effects to patients even though the advised dosing frequency is fully 
complied. These side effects are not always in acceptable levels to patients, especially 
for drug molecules with very high potency, such as cancer drugs. Furthermore, 
repeated dosing is inconvenient to patients especially for those with dementia diseases 
or for those have to constantly go back to hospitals for drug administration. That is 
why the goals of modern pharmaceutical technology are to pursue the prolonged 
duration, the maintenance of the drug plasma concentration level within its 
therapeutic window, the reduced dosing frequency to avoid dose accumulation and to 
enhance the patient compliance. Such goals can be achieved by the application of 
extended (or sustained) drug release technology to modify the drug release rate.  
 
 
 
 4 
 
Figure 1.1. A typical pharmacokinetic level-time curve of a non-intravenous systemic drug delivery 
system after it is administered to a patient: (A) the single dose case, (B) the multiple dose case. 
 
1.2 Extended Release Drug Delivery Systems Controlled by Diffusion  
     Extended release is a term for a dosage form that is modified to protract the 
release rate of its active pharmaceutical ingredient compared to that observed for an 
immediate-release dosage form according to the definition by the United States 
Pharmacopeia Chapter 1151. Drug release from extended release dosage forms is 
rate-controlled by diffusion, dissolution or osmotic pressure. By judiciously utilizing 
these control mechanisms, pharmaceutical companies have successfully put various 
extended release drug products on the market to treat diseases or to be used for other 
clinical applications, such as cancer, hepatitis, central nervous system diseases, 
urologic diseases, intestinal diseases, pain management, and contraceptive 
applications according the U.S. FDA website. Among the three types of mechanisms 
controlling drug release from an extended release drug product, the 
diffusion-controlled mechanism is considered the most promising one because of its 
relatively precise control over release rates for both hydrophobic and hydrophilic drug 
 5 
molecules, its biodegradable property as therapy without surgical operations, and its 
acceptable price to patients [Nair and Laurencin, 2006]. Statistical data (Figure 1.2) 
further indicates that it is widely applied to investigational new drugs with the highest 
activity of currently ongoing human clinical trials among modified drug delivery 
systems [Anselmo and Mitragotri, 2014].  
 
 
Figure 1.2. Normalized pie chart for clinical trial search on clinicaltrials.gov that counts the hits for 
clinical trials that are active and currently ongoing [Anselmo and Mitragotri, 2014]. 
 
Matrix-type and core-shell type biodegradable polymeric microspheres are the 
most common formulations used in commercialized extend release dosage forms 
controlled by diffusion. They are often made of poly(lactic-co-glycolic acid) (i.e. 
PLGA) or polylactic acid (i.e. PLA), two FDA-approved biodegradable synthetic 
polymers without safety concerns to human bodies, to release drugs for longer period 
of time [Nair and Laurencin, 2006; Kerimoğlu and Alarçin, 2012; Nagavarma et al., 
2012; Rytting et al., 2008; Yang and Pierstorff, 2012; Danhier et al., 2012]. 
 6 
Considering the routes they are administered, usually subcutaneous (SC) injection or 
intramuscular (IM) injection [Nair and Laurencin, 2006], these drug-containing 
particles are usually with the sizes no greater than the micron scale. Table 1.1 
summarizes the approved pharmaceutical products containing PLGA-based 
micro-particulate formulations [Kerimoğlu and Alarçin, 2012]. They are mostly given 
to patients as depots to slowly and continuously supply drug molecules into the 
systemic blood circulation, and there are currently no drug products containing 
PLGA-based nanoparticulate formulations in the market [Sah and Sah, 2015]. 
 
 
Table 1.1. PLGA-based microparticles available on the market [Kerimoğlu and Alarçin, 2012]. 
 
     PLGA nanoparticles have been considered potential for intravenous drug 
delivery systems [Muthu, 2009]. Like liposomal particulate formulations, the 
enhanced permeability and retention effect (EPR effect) and the internalization of 
PLGA nanoparticles into cells via endocytosis make PLGA nanoparticles promising to 
be applied to anticancer and antibiotic therapy [Danhier et al., 2012; Davis et al., 
2008]. Table 1.2 summarizes the major pharmaceutical and biopharmaceutical 
characteristics shared by PLGA nanoparticles and liposomal nanoparticles and those 
possessed by PLGA nanoparticles only, suggesting that more research work on PLGA 
 7 
nanoparticles is demanding for their wider clinical applications [Nair and Laurencin, 
2006; Davis et al., 2008; Sipai et al., 2012; Cao et al., 2014; Leonard et al., 2012; Ali 
et al., 2014; Zhang et al., 2008; Beletsi et al., 2005].  
     In view of non-invasive route of drug administration, PLGA formulations are 
promising for local therapies of pulmonary diseases via inhalation drug delivery 
[Ungaro et al., 2012; Ozeki  and Tagami , 2014]. With the large pulmonary surface 
area and extensive blood supply in the alveolar region of the lung, pulmonary drug 
administration is thus also promising for systemic drug delivery, capable of bypassing 
the hepatic first pass metabolism and achieving rapid onset of action with lower doses 
and side effects. However, the intrinsic mucociliary clearance in airways and 
macrophages in alveolar regions hamper the retention of drugs to utilize the bronchial 
circulation for drug absorption. Inhaled PLGA particles smaller than 1 μm have 
potential to reach higher particle deposition percentage in the alveolar region than 
those greater than 6 μm in diameter [HEYDER et al., 1986]. Compared with PLGA 
microspheres, these PLGA nanoparticles are with slower clearance rate by alveolar 
macrophages and minimized elimination by mucociliary clearance, making them 
promising to achieve longer retention time in the deep lung for greater bioavailability 
[Smyth and Hickey, 2011].  
 
 8 
 
Table 1.2. Pharmaceutical and biopharmaceutical characteristics of PLGA and liposomal nanoparticles.  
 
1.3 Methods for the Generation of PLGA Particles  
     Various techniques have been used in published literatures to generate PLGA 
nanoparticles to conduct in vitro or in vivo drug release experiments in order to study 
their potential applications in nanomedicine. Among these techniques, solvent 
evaporation technique, nanoprecipitation technique, and spray drying technique are 
the most frequently used methods, and each of them has its pros and cons. Solvent 
evaporation is a process used to fabricate PLGA nanoparticles by evaporation of the 
water-immiscible organic solvent from droplets generated by emulsifying drug 
solution or drug dispersion in the continuous phase containing surfactants [O’Donnell 
and McGinity, 1997]. Though it has been used to encapsulate either hydrophobic or 
hydrophilic medicaments, encapsulation efficiency of PLGA nanoparticles generated 
with this process is usually low, especially for drug molecules with greater 
 9 
hydrophilicity [Hao et al., 2014; O’Donnell and McGinity, 1997; Popa and Dumitriu, 
2013]. Moreover, the broad size distribution of the prepared particles is another 
shortcoming of this process, which affects drug release behaviors of PLGA 
nanoparticles and their interactions with cells [Sah and Sah, 2015]. Slightly different 
from solvent evaporation technique, a nanoprecipitation process involves evaporation 
of the organic solvent after injecting the drug-containing polymer solution into a 
stirred continuous phase containing surfactants. Fast diffusion of the water-miscible 
solvent then causes deposition of PLGA at the interface between water and the 
organic solvent and instantaneous formation of nanoparticles [Nagavarma et al., 2012]. 
Compared with the solvent evaporation process, the nanoprecipitation process is a 
relatively mild one since high energy input is not required. The process can be 
accomplished without any surfactants added into the continuous phase by using 
suitable benign solvents, which greatly minimize the concerns with toxicity caused by 
solvents and surfactants. However, removal of benign organic solvents is challenging 
because of their low volatility. Despite some attempts to improve the drug loading, the 
encapsulation efficiency of PLGA nanoparticles generated via the nanoprecipitation 
technique, especially for hydrophilic drug compounds, is usually low [Schubert et al., 
2011]. Spray drying is another method often used to generate PLGA nanoparticles. Its 
first application comes from the year 1860 and is adaptable in an industrial scale as 
continuous and automatic control [Guterres et al., 2009; Cal and Sollohub, 2010; Mu 
and Feng, 2001]. Generally speaking, spray drying is to transform the feed in a fluid 
state into the product in a dried particulate form by spraying the feed into a gaseous 
drying medium [Patel et al., 2009; Cal and Sollohub, 2010]. Like solvent evaporation, 
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the spray drying technique can be used to encapsulate hydrophilic and hydrophobic 
drug compounds into PLGA nanoparticles [Mu and Feng, 2001; Guterres et al., 2009]. 
However, the conventional spray drying technique is incapable of generating PLGA 
particles with special internal structures to provide diverse biopharmaceutical 
applications [Patel et al., 2009].  
     In view of the facts mentioned above, the electrospray (ES) technique is 
considered excellent to be used to generate PLGA nanoparticles because it possesses 
all advantages and overcomes all disadvantages of aforementioned techniques. By 
applying the electrospray technique, monodisperse PLGA nanoparticles can be 
generated in a large scale via a single step process which is potential for industrial 
applications in the future [Lee et al., 2010; Sridhar and Ramakrishna, 2013]. The 
electrospray process can encapsulate drug molecules into PLGA nanoparticles with 
significantly higher encapsulation efficiency compared with conventional particle 
generation processes regardless of hydrophilicity and molecular weight of the loaded 
drug molecules [Bock et al., 2012; Lee et al., 2010; Hao et al., 2014]. Furthermore, it 
can also be used to generate PLGA nanoparticles with unique structures for less extent 
initial burst release compared with those generated via conventional particle 
generation techniques [Lee et al., 2010]. Content of residual solvents used during the 
particle generation process is relatively lower than conventional particle generation 
processes in the liquid phase, leading to less safety concerns for potential 
biopharmaceutical applications [Bock et al., 2012, Bai and Yang, 2013; Rezvanpour 
et al., 2010].  
     According to aforementioned background information, the motivation of this 
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study is therefore to employ the electrospray technique to generate biocompatible 
PLGA nanocomposite with unique configurations to deliver drugs. Because of the 
increasing importance of the fixed-dose combination therapy to patients requiring 
multiple therapies for simplified disease management and enhanced medication 
concordance, drug release behaviors of co-encapsulated combination drugs with 
significant differences in hydrophilicity and molecular weights from matrix-type and 
core-shell type PLGA nanoparticles are investigated, and release profiles of the single 
active agent encapsulated in a single dosage formulation are also studied as a 
reference for the combination PLGA nanoparticulate formulations. Through this 
research, we expect to provide general principles from systematic release profile 
studies for sustained release and/ or sequential release of fixed-combined hydrophilic 
and hydrophobic active ingredients from PLGA nanoparticles for their potential 
biopharmaceutical applications in inhalation therapy and cancer therapy.  
 
1.4 Review of Drug Delivery with ES PLGA Nanoparticles  
1.4.1 Matrix-type PLGA Nanoparticles Generated by the Single Capillary ES  
     Though electrospray technique has been studied for more than 100 years, it has 
begun to be applied to generate micro-/nano-structured materials since 1990s [Xie et 
al., 2015]. Due to the progress of nanomedicine and the limitations of employing 
conventional methods to produce PLGA nanoparticles, electrospray has brought to the 
attention for its advantages to generate PLGA nanoparticles for encapsulation and 
extended release of therapeutics since 2000s.  
     Challenges of formulating hydrophobic medicaments according to modern 
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pharmaceutical science reveal the fact that PLGA micro-/nano-particles could be a 
useful formulation to deliver drugs with low water solubility. Xie et al. (2006) [Xie et 
al., 2006] reported that Paclitaxel, a highly hydrophobic small molecule used for 
cancer treatment, can be encapsulated into PLGA particles with size ranging from 355 
nm to 1.2 μm by adjusting the feed flow rate of spray liquid and the concentration of 
PLGA. They also found that a higher PLGA concentration is helpful to generate 
PLGA particles with smooth surface and spherical morphologies. Though they didn’t 
test the encapsulation efficiency of the PLGA particles generated in their research, 
their results demonstrated that PLGA nanoparticles can be used to encapsulate 
hydrophobic drug molecules. Similar research was done later by Valo et al. in 2009 
[Valo et al., 2009] that both hydrophilic and hydrophobic model drugs, Salbutamol 
sulfate and Beclomethasone dipropionate respectively, were successfully encapsulated 
in 200-nm PLA particles with narrow size distribution. Drug encapsulation efficiency 
was higher than 50% regardless of hydrophilicity of the drug, demonstrating that 
electrospray is more efficient than conventional techniques based on liquid phases to 
encapsulate both hydrophilic and hydrophobic drugs. They also claimed that 
electrospray can be used to co-encapsulate a hydrophilic and a hydrophilic drug 
molecule in matrix-type PLGA nanoparticles. However, they didn’t actually prove the 
feasibility of their claim with data. The above two published scientific articles 
reported the capability of electrospray to encapsulate small molecule drugs, yet they 
didn’t address how drugs are released from the vehicles. 
     In 2011, Almería et al. [Almería et al., 2011] utilized the single nozzle 
electrospray technique, the multiplexed electrospray technique, and the solvent 
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evaporation technique to encapsulate three molecules with different hydrophilicity, 
which were Rhodamine B (RHOB), Rhodamine B octadecyl ester perchlorate 
(RHOBOEP) and Doxorubicin hydrochloride (DOX). Through a series of comparisons, 
they concluded that release rates of the hydrophilic and the hydrophobic drug 
molecules were both greater when encapsulated in matrix-type electrospray 
nanoparticles with smaller particle size. Higher drug release rate was observed for the 
drug with greater hydrophilicity due to the less affinity between the drug and PLGA. 
They also confirmed that the technique used to produce PLGA nanoparticles didn’t 
significantly affect drug release profiles for the same drug compound regardless of the 
hydrophilicity of the loaded drug. Through systematic studies, the results of this 
research help us learn the effects of particle size, particle generation methods, and the 
hydrophilicity of drug on drug release profiles of PLGA nanoparticles.  
     Drugs classified as Class 1 according to the Biopharmaceutical Classification 
System (BCS) defined by U.S. FDA are suitable to be formulated into conventional 
immediately release dosage forms because of the high water solubility and the 
easiness to cross biological membranes to be absorbed. However, they are also easy to 
be excreted by Kidney, except for antibody therapeutics with extremely high 
molecular weights, meaning that t.i.d. or q.i.d. dosing frequencies are usually needed 
especially for BCS Class 1 drugs with short half-lives in human body. That is why 
extended release formulations for hydrophilic drugs having short half-lives are with 
great values. 
     N-Acetylcysteine (NAC) is a hydrophilic small molecule drug containing a 
thiol group. It possesses antioxidant and mucolytic properties and is often used to treat 
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neuroinflammation, fibrosis, cartilage erosion and acetaminophendetoxification. Its 
low oral bioavailability and high plasma protein binding tendency after intravenous 
administration make it suitable to be encapsulated with PLGA nanoparticles as 
protection away from plasma proteins. Previous studies performed by Zarchi et al. 
(2015) [Zarchi et al., 2015] showed that NAC can be efficiently encapsulated, with 
encapsulation efficiency greater that 50%, in PLGA particles smaller than 150 nm by 
employing optimized electrospray process parameters. The resultant nanoparticles 
performed extended release of NAC for greater than 2 days in vitro, suggesting the 
potentials of PLGA nanoparticles smaller than 150 nm to be applied to hydrophilic 
small molecule drug delivery.  
     Due to the successful research results of the matrix-type PLGA nanoparticles 
generated via electrospray to encapsulate and to slowly release both hydrophilic and 
hydrophobic drugs in vitro, further studies have been done for its application in 
targeted drug delivery systems for high potency drugs. Bai et al. (2014) [Bai and Liu, 
2014] proposed to use a single nozzle electrospray process to generate polyethylene 
glycol-poly(lactic-co-glycolic acid) (PEG-PLGA) nanoparticles. Compared with 
conventional methods requiring bioconjugation reactions to synthesize PEG-PLGA 
first before particle generation procedures, results of FTIR and NMR confirmed the 
maleimide moiety of PEG intact as incorporated into resultant nanoparticles after the 
electrospray processing. The intact maleimide moiety ensures the successful coupling 
of CD44 antibody through a chemical reaction between its thiol group and the 
maleimide moiety of PEG-PLGA nanoparticles. In vitro cell studies showed 
significant effectiveness of the Cisplatin-loaded CD44-PEG-PLGA nanoparticles on 
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antiproliferation of CP70 and SKOV ovarian cancer cell lines. Based on our literature 
review, this is the first study to generate antibody-PEG-PLGA nanoparticles with the 
electrospray technique and to confirm their anticancer effectiveness via in vitro cell 
studies, even though they didn’t study in vitro drug release profiles of the as-produced 
nanoparticles.  
 
1.4.2 Core-shell Type PLGA Nanoparticles Generated by the Coaxial Dual 
Capillary ES 
     Like Section 1.4.1, numerous studies have been done to learn drug 
encapsulation, drug release and biological effectiveness of core-shell type PLGA 
nanoparticles generated via the coaxial dual capillary electrospray (ES) technique.  
     The polymer concentration of the outer liquid in a dual capillary electrospray 
process affects size of the particles. Generally speaking, a higher polymer 
concentration in outer polymer coating solution leads to larger particle size and vice 
versa. With this principle, Enayati et al. (2010) [Enayati et al., 2010] generated 
core-shell type PLGA particles with the size ranging from 120 nm to a few 
micrometers via adjusting the PLGA concentration of the spray liquid in the outer 
layer. Estradiol, a hydrophobic sex hormone with low oral bioavailability, was 
encapsulated in the core of these nanoparticles with encapsulation efficiency close to 
70% and continuously released up to 20 days in vitro. The size effect was also 
reported in their research. Among the particles studied, drug release rate of Estradiol 
was faster from PLGA nanoparticles with smaller particle sizes because of their 
higher surface area to volume ratio. Nonetheless, drug release profiles were biphasic 
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regardless of the sizes of particles been studied. 
     To compare the performances of different types of formulations, Bai et al. 
(2013) [Bai and Yang, 2013] formulated Niclosamide, a hydrophobic compound used 
for the treatment of tapeworm infections, into electrosprayed Niclosamide, 
matrix-type PLGA nanoparticles, and core-shell type PLGA nanoparticles. The 
conventional Niclosamide solution formulation, dissolving Niclosamide in DMSO, 
was prepared and studied as the control group. Their results showed that the 
electrosprayed Niclosamide performed fastest drug release rate among all the 
formulations within 500 hours of test time because of its extremely high surface area 
to volume ratio and the uncontrolled release behaviors without PLGA in the 
formulation. During the same period of time, the drug release rate of the core-shell 
nanoparticles was always lower than that of the matrix-type nanoparticles yet the 
two-stage release profile could be clearly observed for the case of core-shell particles. 
Though both matrix-type and core-shell type PLGA nanoparticles exhibited greater 
drug release rates than electrosprayed Niclosamide due to the dose dumping 
phenomenon after the 500th hour of the release studies, such a finding was considered 
with limited use in reality by the author. The results of in vitro cell studies confirmed 
the greatest antiproliferation effectiveness of the electrosprayed matrix-type PLGA 
nanoparticles against ovarian cancer cells among all the tested formulations because 
of its large surface area to volume ratio and easiness to be incorporated into cells. The 
antiproliferation effectiveness of the electrosprayed core-shell type PLGA 
nanoparticles was surprisingly the lowest because of the slowest drug release rate 
controlled by particle structure.  
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     Similar research was done by Lee et al. (2010) [Lee et al., 2010] to address the 
size effect and the structure effect of PLGA nanaparticles on drug release behaviors. 
Unlike the aforementioned studies, they employed the coaxial dual capillary 
electrospray technique and the solvent evaporation technique to encapsulate 
Budesonide, a hydrophobic drug compound, into the cores of the core-shell type 
PLGA nanoparticles and the matrix-type PLGA nanoparticles, respectively. In their 
results, particles smaller than 200 nm were successfully generated via electrospray 
with around 89.9% encapsulation efficiency, which was confirmed to be significantly 
higher than that of particles generated via the solvent evaporation technique. Due to 
the lesser surface loaded drugs, the core-shell type nanoparticles performed less 
severe initial burst release and continuously released Budesonide for more than two 
days. Particles with sizes ranging from 165 nm to 1.2 μm were generated by 
optimized electrospray process parameters through a thorough study on the effects of 
electric conductivity and polymer concentration of the outer spray liquid. Particles 
with smaller sizes were confirmed to release encapsulated Budesonide with a higher 
release rate than larger particles, which was concluded to be associated with pin holes 
formed on the surface of smaller particles as a result of the infusion of the 
surrounding release media into the particles. The encapsulation of epigallocatechin 
gallate (EGCG), a hydrophilic compound, into the matrix-type and the core-shell type 
PLGA nanoparticles was also studied in their research. Though the drug release 
profiles of EGCG were not studied, a significantly higher encapsulation efficiency of 
EGCG in electrospray core-shell PLGA nanoparticles than that in matrix-type PLGA 
nanoparticles produced by the solvent evaporation technique was reported.  
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     Further research on coaxial dual capillary electrospray technique for 
hydrophilic drug delivery has been done after Lee’s research published in 2010 for 
cancer treatment. 5-Aminolevulinic acid (ALA) is a natural amino acid synthesized by 
animal and plant mitochondria. It is often applied to the Photodynamic Therapy (PDT) 
as an important approach to treat solid tumors. Under physiological conditions, ALA 
is metabolized into Protoporphyrin IX (PpIX) by the heme biosynthesis. The resultant 
PpIX inherently tends to target tumors and requires much more time to be degraded in 
cancer cells than in normal cells. By applying photo excitation of light with special 
wavelength, the reactive oxygen species (ROX) is generated to perform anti-tumor 
activities. Due to the poor stability in the physiological environment, biodegradable 
drug carriers are considered promising to the delivery of ALA. Gual et al. (2015) 
[Guan et al., 2015] encapsulated ALA into core-shell structure PLGA nanoparticles 
with sizes ranging from 200 nm to 1 μm by adjusting the outer and the inner flow rate 
ratio. The reported encapsulation efficiencies of all the particles in their study were 
higher than 60% to slowly release ALA for more than 7 days. For nanoparticles, their 
results suggest that the smaller particle size did not necessarily result in greater drug 
release rate. Higher drug encapsulation efficiency in larger nanoparticles could also 
lead to faster drug release rate than that of smaller nanoparticles when these smaller 
particles were with lower encapsulation efficiency. Higher fluorescent intensity of 
intracellular PpIX in HSC-3 cells confirmed that the 200-nm electrosprayed PLGA 
nanoparticles were capable of delivering ALA into cells compared with the control 
group that no treatment was applied to HSC-3 cells. 
     The layered structure of PLGA nanoparticles makes them suitable to deliver 
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more than one medicament simultaneously. Due to the overly expressed efflux pumps 
usually seen in cancer cells, the coaxial dual capillary electrospray technique is 
promising to generate core-shell type PLGA nanoparticles for combination 
chemotherapy. Cao et al. (2014) [Cao et al., 2014] co-encapsulated Combretastatin A4 
(CA4, a hydrophobic anti-angiogenesis agent) and Doxorubicin (DOX, a relatively 
hydrophilic drug molecule compared with CA4) in the shell and core of the 
nanoparticles, respectively. They also added biodegradable/ biocompatible polymers 
with different hydrophobic properties, i.e., the hydrophilic polyvinylpyrrolidone (PVP) 
and the hydrophobic poly(3-caprolactone) (PCL), in inner drug solution during the 
electrospray process to tailor release profiles of these dual drug loaded particles. Due 
to the high intermolecular affinity between CA4 and PLGA, slower release rate was 
always observed for CA4 even though it was encapsulated in the shell region 
regardless of the hydrophobicity of polymers in the core region. In addition, a higher 
release rate was observed for both CA4 and DOX when PVP was formulated in the 
core region resulted from greater influx of the surrounding release media into particles. 
Results of cell studies also demonstrated the melanoma cells B16-F10 and human 
umbilical vein endothelial cells (HUVECs) were sequentially targeted and killed by 
DOX and CA4 sequentially released from the particles.  
     In view of the importance of biomolecules in clinical applications and the 
potentials of core-shell type PLGA nanoparticles for combination chemotherapy, 
Wang et al. (2015) [Wang et al., 2015] employed the electrospray technique to 
encapsulate Bone morphogenetic protein 2 (BMP-2) and Vascular endothelial growth 
factor (VEGF) in the core and shell of the PLGA nanoparticles, respectively. Because 
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of the PLGA and PLA formulated in the core and shell, respectively, in these particles, 
drug release profiles of both BMP-2 and VEGF were better controlled than same 
drugs co-encapsulated into matrix-type PLGA nanoparticles produced via the single 
nozzle electrospray technique. Moreover, drug release behaviors of co-encapsulated 
BMP-2 and VEGF were independent with each other by comparing their release 
profiles from core-shell structure PLGA nanoparticles containing BMP-2 or VEGF 
individually. Results of in vitro cell studies and in vivo animal studies confirmed the 
effectiveness of the proposed core-shell PLGA nanoparticles on cell proliferation and 
the growth of bone tissues and blood vessels. This study indicated that core-shell type 
PLGA nanoparticles loaded with BMP-2 and VEGF could stimulate angiogenesis and 
osteogenesis to be applied to post-surgical repair of large bone defects.  
     As a conclusion of our literature review, great efforts have been made through 
previous studies to identify the key process parameters of electrospray and how these 
parameters affect size, size distribution and morphology of the resultant PLGA 
nanoparticles. Factors affecting rates of drug release from electrosprayed PLGA 
nanoparticles have also been identified as a reference to tailor their drug release 
behaviors for potential biopharmaceutical applications. Compared with conventional 
particle generation methods based on liquid phase, electrospray can often maintain the 
activity of the loaded drug and reach significant higher drug encapsulation efficiency 
regardless of the hydrophilicity of the loaded drugs, which is crucial prerequisite for 
extended drug release. Due to the simplicity of an electrospray process, key moiety 
for chemical reactions can be directly incorporated into PLGA nanoparticles, which 
greatly ensures successful coupling of antibody to particles for the applications of the 
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target therapy. Comparisons regarding in vitro drug release profiles and effectiveness 
through cell studies have been done for both hydrophilic and hydrophobic drugs 
encapsulated into PLGA nanoparticles with different internal configurations by either 
the electrospray technique or the solvent evaporation technique. However, limited 
studies have been done to systematically characterize in vitro drug release profiles of 
combination therapy encapsulated in PLGA nanoparticles with unique configurations. 
Because electrospray is a one-step process capable of generating particles with 
different conformations, we utilize the electrospray process in this dissertation work 
to produce drug-loaded PLGA nanoparticles with unique configurations and 
systematically investigate their resultant drug release behaviors. Key factors 
influencing drug release behaviors from PLGA nanoparticles are also identified to 
learn how to slowly release loaded drugs from ES PLGA nanoparticles for their 
biopharmaceutical application in combination therapy.  
 
1.5 Research Objectives  
The aim of this dissertation work is to advance our knowledge of in vitro drug 
release of one or two pharmacologic agents with varied hydrophilicity and molecular 
weights from PLGA nanoparticles with unique structures. Accordingly, the objective 
of this work is to investigate in vitro release profiles of drug-loaded PLGA 
nanoparticles to identify key factors that are critical for extended drug release and 
sequential drug release.   
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2.1 Preparation of Drug-loaded PLGA Nanoparticles  
     Electrospray (also called electrohydrodynamic spray) is a liquid atomization 
phenomenon caused by electrical forces [Bock et al., 2012; Jaworek and Sobczyk, 
2008]. Figure 2.1 is a schematic representation of a typical electrospray setup with the 
point-to-plate configuration [Hao et al., 2014]. An electrospray (ES) process begins 
with the deformation of the interface of a liquid droplet exiting a capillary by the 
electric field created by the applied high voltage on the capillary. The resultant 
electric charges generate electrostatic forces to compete and eventually to balance 
with surface tension of the droplet to reach the cone-jet mode operation. A thin jet is 
then ejected from the apex of the cone, and smaller micro-/nano-charged droplets are 
formed via jet breakup by coulomb repulsion to dissipate excess charges. Finally, 
ejected droplets are dried via evaporation of the spray solvent, and dry particles are 
collected on surface of the grounded substrate [Hao et al., 2014; Bock et al., 2012; 
Xie et al., 2006].  
     Dripping mode, silver bullet mode, pulsating mode, cone-jet mode, and multijet 
mode are the five modes that are usually seen during the operation of an electrospray 
process. Among them, the cone-jet mode holds a conspicuous position because it can 
be used to generate monodisperse particles [Chen et al., 1995; Mei and Chen, 2008]. 
Key process parameters of an electrospray process, such as the feed flowrate, the 
electric conductivity and the polymer concentration of the spray liquid, for PLGA 
micro-/nano-particle generation have been investigated and identified by previous 
studies. The results have been discussed in previous literature review sections on 
sustained drug release with PLGA particles produced by the electrospray technique. 
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Except for the key process parameters, spray solvent and the tip-to-collector (TTC) 
distance of the electrospray setup also affect morphology and monodispersity of the 
as-produced PLGA particles [Bock et al., 2012; Park and Lee, 2009]. Increasing the 
TTC and selecting a solvent, or a combination solvent system, with slower 
evaporation rate help enhance monodispersity and spherical morphologies of the 
resultant PLGA particles for favorable release behaviors [Bock et al., 2012; Park and 
Lee, 2009].  
 
 
Figure 2.1. A schematic representation of a typical electrospray setup with the point-to-plate 
configuration [Hao et al., 2014]. 
 
In this dissertation work, an electrospray setup with the point-to-plate 
configuration was employed to generate and collect PLGA nanoparticles as shown in 
Figure 2.2. During the electrospray process, spray solutions, containing PLGA and/ or 
loaded drugs, were injected in the flow channels of the nozzle by programmable 
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syringe pumps (Harvard, Model PHD 2000). A positive DC voltage, via DC high 
voltage power supply (Bertan 230), was applied to the nozzle to help overcome 
surface tension of the spray liquids for generating monodisperse PLGA nanoparticles 
under cone-jet mode operation, monitored via a video microscope (Infinity, Model: 
K2 DistaMax) and a digital camera (Edmund optics, Model: 2013C LE). Mildly 
heated compressed dry air was also applied in our electrospray system to facilitate the 
evaporation of the solvents in sprayed droplets. A grounded substrate was placed 
under the nozzle at a proper distance away from its tip to collect the as-produced 
particles. The setup of the single capillary electrospray open system and the coaxial 
dual capillary electrospray open system are similar but different in type of the nozzle 
and the number of flow channels and syringe pump included in the process setup.  
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Figure 2.2. Schematic diagrams of (A) the single capillary electrospray process setup and (B) the 
coaxial dual capillary electrospray process setup used to generate matrix-type and core-shell type 
PLGA nanoparticles, respectively.  
 
2.2 Characterization of Morphology and Size Distributions of PLGA Particles  
The size distribution of prepared particles were primarily measured by either a 
scanning mobility particle sizer, SMPS (TSI Model 3081) for particles in the sizes 
ranging from 3 nm to 700 nm in diameter or an optical particle sizer, OPS (TSI Model 
3330) for particles in the sizes ranging from 100 nm to 10 μm. Instead of an open 
system, a close electrospray system with a charge reduction chamber was connected 
with particle sizing instruments and used in this part of characterization. The 
differences between the electrospray open system and the close system are the 
grounded electrode and the charge reduction scheme applied to the close system only. 
In the close system, an aluminum orifice with 0.25 inches in diameter is placed at 
approximately 15 mm below tip of the nozzle as the grounded electrode. The carry air 
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flow of 10 liters per minute is used to transport the sprayed particles into the charge 
reduction chamber, where electrical charges of sprayed particles are minimized with 
four radioactive sources (Po210; MOD: P-2042) to reduce particle loss in the system. 
The charge-reduced particles are then sent into particle sizers for the characterization 
of their size distributions. Data from particle sizers were recorded in a PC for further 
analysis. The schematic diagram of the coaxial dual capillary electrospray close 
system along with a SMPS is illustrated in Figure 2.3 for the characterization of size 
distributions of core-shell type PLGA particles in the sizes ranging from 3 nm to 700 
nm in diameter. The nozzle in the close electrospray system and the particle sizer are 
both replaceable for characterizing either matrix-type or core-shell type PLGA 
nanoparticles in different size ranges. The morphology of the prepared drug-loaded 
PLGA particles was also characterized by SEM (Hitachi, Model: SU-70 FE-SEM). 
Prior to SEM, the particle samples were sputtered with Platinum for 90 seconds 
(Denton Vacuum, Model: Desk V). The magnification of the SEM is 20x-800,000x.  
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Figure 2.3. A schematic diagram of the electrospray close system along with a Scanning Mobility 
Particle Sizer (SMPS) to characterize size distributions of ES PLGA nanoparticles.  
 
2.3 In vitro Drug Release Testing Procedures  
     In vitro drug release testing, or dissolution testing, is a commonly used tool in 
preclinical research within the pharmaceutical industry to study the performance of 
developing dosages and to monitor batch-to-batch quality control for mass production. 
It has been employed to investigate in vitro drug release behaviors of the myriad of 
dosage forms, such as transdermal patches, suspensions and chewing gums, though it 
was recommended for solid oral dosage forms in the beginning [Betageri et al., 2011]. 
Currently available mainstream methods to study release kinetics from 
nanoparticulate drug carriers are (i) dialysis; (ii) sampling and separation by using 
centrifugation [Betageri et al., 2011]. Both methods have been widely used previously, 
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generating in vitro drug release data for nanoparticles with the dialysis method and the 
centrifugation method in nearly forty and fifty cases of about ninety published 
literature articles, respectively, in 2011 [Zambito et al., 2012]. In order to establish a 
standardized procedure of the in vitro drug release testing on drug-loaded PLGA 
nanoparticles for this dissertation work, feasibility of the dialysis method for drug 
release testing was first studied in the following Section 2.3.1.  
 
2.3.1 Investigation of the Dialysis Method  
The application of colloidal drug carriers in drug delivery is getting greater 
attention recently. However, the separation of nanoparticles from the release media is 
challenging due to the very small size of the particles. Stronger centrifugal forces are 
therefore used in order to cleanly separate particles from the media, which often leads 
to inaccurate drug release results because the integrity of the nanoparticles is affected 
[Abdel-Mottaleb and Lamprecht, 2011]. Moreover, the accuracy of drug release 
results is also impacted because drug carriers are still releasing the encapsulated drugs 
during the centrifugation process.  
     Because the diffusion of drugs across the dialysis membrane can be the 
rate-limiting step of dialysis, feasibility of the dialysis method as a standardized 
procedure for in vitro drug release testing was assessed by studying the diffusion of 
Budesonide (the hydrophobic model drug) across the dialysis membrane with the 
apparatus shown in Figure 2.4. The dialysis bag (Spectrum®, Float-A-Lyzer, 
Molecular weight cutoff: 0.5-1 kD) had been pretreated by sequentially soaked in 40 
ml 10% ethanol, DI water and PBS for 10 minutes, 20 minutes and overnight, 
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respectively, before dialysis was initiated. To learn whether Budesonide can diffuse 
from the donor phase (i.e., inside the dialysis bag) into the receiving phase (i.e., 
outside the dialysis bag), 10 μg Budesonide were dissolved in the 1-ml phosphate 
buffered saline (PBS, 0.02 M, pH 7.4), and the 1-ml Budesonide PBS solution was 
put in the dialysis bag. The bag was then put into a 50-ml glass beaker containing 40 
ml PBS as the receiving phase with gentle stir. During the dialysis study, 1.5 ml PBS 
solution was sampled from the receiving phase along with equal volume of fresh PBS 
filled to the receiving phase at each sampling time. In the end of the 12-hour dialysis 
study, Budesonide concentrations in the dialysis bag and in the PBS sampled at 
pre-determined time intervals from the receiving phase were measured by HPLC. The 
cumulative mass of Budesonide in the receiving phase is displayed in Figure 2.5, 
evidencing the fact that the amount of Budesonide diffusing from the donor phase to 
the receiving phase was extremely small at each sampling time during the dialysis 
process. However, Budesonide concentrations in the donor phase before and in the 
end of the dialysis study were 10 μg/ml and 0.17 μg/ml, respectively, suggesting the 
fact that around 9.83 μg of Budesonide was leaving the donor phase during the 
dialysis process. The above finding implies potential interactions between Budesonide 
and the dialysis membrane. Therefore, the dialysis method is not a capable 
methodology to be used for in vitro drug release testing in the present dissertation 
study.  
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Figure 2.4. A schematic diagram of the dialysis apparatus for studying diffusion of Budesonide across 
the dialysis membrane.  
 
 
Figure 2.5. Cumulative mass of Budesonide detected in the 40-ml receiving phase (0.02 M PBS, pH 7.4) 
during the 12-hour dialysis study.  
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2.3.2 Drug Release Testing Procedures with the Centrifugation Method  
     Previous research has proven that the dialysis method is not necessarily 
discriminating to generate descriptive data for significant comparison between 
different formulation parameters of nanoparticulate drug carriers [Zambito et al., 2012; 
Abdel-Mottaleb and Lamprecht, 2011]. Our earlier studies in Section 2.3.1 also 
indicated that the dialysis method is not an appropriate method for in vitro drug 
release testing for the tested model drugs.  
     In the present dissertation work, we utilized the centrifugation method to 
characterize drug release considering the fact that physical or chemical interactions 
between the test drugs and the dialysis membranes could affect the resultant release 
profiles. Moreover, the method also endued us with greater research flexibility to 
select drug compounds to be studied instead of been restricted by currently available 
dialysis membranes on the market. The procedures of the centrifugation method and 
the recipe of the release media are as follows:  
Procedures of the centrifugation method: 
(1) Incubated PLGA particles attached on the surface of an aluminum foil in a 
15-ml plastic centrifugation tube containing 10 ml 0.02 M PBS (pH=7.4, 
[NaCl]=0.15 M) as the release media with the Shaker Water Bath (Thermo 
Scientific, Model: Precision 2870, setting: 40 RPM, 36.5 oC). The 
optimized volume of the release media (i.e., 10 ml PBS) for the thesis study 
was determined by performing in vitro drug release testing on Budesonide 
encapsulated in 70-80 nm ES matrix-type PLGA (Mw: 7,000-17,000 g/mol, 
LA/GA: 50/50) nanoparticles (Budesonide-to-PLGA mass ratio: 2:10) and 
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comparing the resultant drug release profiles in various volumes of release 
media (i.e., 4 ml, 10 ml and 40 ml). Figure 2.6 depicts the Budesonide 
release profiles in different volumes of the release media. The result 
indicates that the drug release rate in greater volume of release media was 
higher on account of the greater driving force for drug diffusion. In view of 
our currently available bench-top centrifuge used to collect release media 
during drug release experiments, we chose 10 ml 0.02 M PBS ([NaCl]=0.15 
M, pH=7.4) as the release media throughout the thesis work.  
(2) Removed the aluminum foil from the plastic centrifugation tube at the 
pre-determined time intervals.  
(3) Centrifugalized the tube with a bench-top centrifuge (eppendorf, Model: 
5417C) at 14,000 RPM for 20 minutes to collect all release media and to 
minimize the loss of detached particles from the aluminum foil.  
(4) Put the aluminum foil back into the plastic centrifugation tube and refilled 
the tube with fresh release media.  
(5) Incubated the tube in a Shaker Water Bath till the next pre-determined time 
interval for another sampling.  
(6) Quantified the amount of the released drug in the release media sampled at 
pre-determined time intervals by HPLC (Agilent, Model: 1260) or by a 
protein assay detected by an ELISA plate reader (BioTek, Model: Synergy 
H1).  
 
Recipe and preparation protocol of the release media: 
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     Step 1: Dissolved the following compounds in 600 ml distilled water. 
NaH2PO4: 0.54 g.  
Na2HPO4: 1.06 g. 
NaCl: 5.26 g. 
Step 2: Adjusted pH to 7.4. 
 
 
Figure 2.6. Budesonide release profiles of 70-80 nm PLGA (Mw: 7000-17000 g/mol, LA/GA: 50/50) 
particles in different volumes of release media (0.02 M PBS, [NaCl] = 0.15 M, pH = 7.4).  
 
2.4 Analytical Method Development for Quantification of the Loaded Drugs  
2.4.1 HPLC Analytical Method Development for the Quantification of the 
Small-molecule Model Drugs  
     In order to quantify the amount of drugs released from PLGA nanoparticles in 
the release media, reliable HPLC analytical methods of small-molecule model drugs 
have been developed based on our lab facilities. This was done in order to 
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characterize drug release profiles for the tested nanoparticulate formulations. The 
Agilent 1260 HPLC system composed of a quaternary pump, a standard autosampler, 
a thermostatted column compartment, a ZORBAX SB-C18 2.1 x 150 mm, 3.5 μm 
column, and a diode-array detector was used throughout this research. Acetonitrile, 
Methanol, and pure water were the solvents for the mobile phase.  
A literature review has been conducted for HPLC analytical methods of 
Budesonide [Gupta and Bhargava, 2006; Naikwade and Bajaj, 2008; United States 
pharmacopeia 35 (2012)], Theophylline [Kanakal et al., 2014; Oprea et al., 2012; 
Bispo et al., 2002] and Paclitaxel [Cho et al., 2004; Fonseca et al., 2002]. Through the 
optimization of HPLC parameters, such as the injection volume of each sample, UV 
wavelength setting of the detector, flow rate and composition of the mobile phase and 
the column compartment temperature, the finalized analytical methods are 
consolidated as below along with standard curves made by measuring samples of 
known concentrations with the optimized operation condition. All R-square values of 
standard curves in the analytical methods of Budesonide, Theophylline and Paclitaxel 
were greater than 0.999, confirming the accuracy of the methods that we have 
developed for our small-molecule model drugs. The developed HPLC analytical 
methods and the corresponding standard curves of the small-molecule model drugs 
are consolidated as follows:  
  HPLC parameters for Budesonide measurement: 
 Mobile phase: Methanol/ H2O (80/20) 
 Flow rate: 0.25 ml/ min 
 Column: Zorbax C-18 (2.1 x 150 mm, 3.5 μm) 
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 Detection UV wavelength: 244 nm 
 Injection volume: 2 μl 
 Column temperature: 20 oC 
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Figure 2.7. The standard curve of the HPLC analytical method of Budesonide. 
 
  HPLC parameters for Theophylline measurement: 
 Mobile phase: H2O/ Acetonitrile (90/10) 
 Flow rate: 0.25 ml/ min 
 Column: Zorbax C-18 (2.1 x 150 mm, 3.5 μm) 
 Detection UV wavelength: 271 nm 
 Injection volume: 2 μl 
 Column temperature: 20 oC 
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Figure 2.8. The standard curve of the HPLC analytical method of Theophylline. 
 
  HPLC parameters for Paclitaxel measurement: 
 Mobile phase: H2O/ Acetonitrile (45/55) 
 Flow rate: 0.25 ml/ min 
 Column: Zorbax C-18 (2.1 x 150 mm, 3.5 μm) 
 Detection UV wavelength: 227 nm 
 Injection volume: 3 μl 
 Column temperature: 20 oC 
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Figure 2.9. The standard curve of the HPLC analytical method of Paclitaxel. 
 
2.4.2 The Protein Assay for the Quantification of Bovine Serum Albumin (BSA)  
Protein assays are the methods used to estimate protein concentration. It has 
been extensively applied to molecular biology, cell biology, protein purification and 
many other applications in life science research. A myriad of protein assays are 
currently available in the market with different reliable protein concentration ranges 
of detection. Each of them has its own advantages and limitations, particularly 
considering their buffer compatibilities. None of the protein assays is capable of 
yielding absolutely accurate results on its own. Therefore, the suitability of a protein 
assay should be carefully considered according to its research applications [Ernst and 
Zor, 2010; Olson, 2016].  
     Herein, the NanoOrange® Protein Quantification Kit was used to measure the 
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concentration of Bovine Serum Albumin (BSA) in the release media. Compared to 
other assays for protein quantification in aqueous solutions, the NanoOrange assay is 
advantageous with lower protein-to-protein signal variability. Detection of the 
samples is not influenced by nucleic acids or reducing agents according to the product 
information. Samples can be read up to six hours after been prepared with extremely 
limited loss of sensitivity, making the assay convenient and reliable for lab use. By 
employing the 200 μl microplate assays, the linear working range of the assay are 
between 100 ng/ml and 10 μg/ml. The detailed operational protocol of the 
NanoOrange protein assay and its standard curve for the estimation of protein 
concentration are as follows:  
Procedures of the NanoOrange® Protein Quantification Kit for quantification 
of BSA: 
(1) Prepared 1X protein quantification diluent by mixing the concentrated 
NanoOrange® protein quantification diluent and diluting 10-fold in distilled 
water.  
(2) Prepared 1X NanoOrange® reagent working solution by diluting the 
NanoOrange® protein quantification reagent (i.e., Component A of the Kit) 
500-fold into the 1X protein quantification diluent from step (1). The 
as-prepared working solution needed to be protected from light. All the 
following steps were also performed in an environment without influencing 
by light.  
(3) Mixed 10 μl BSA solution having unknown concentration with 240 μl 
working solution in an eppendorf with a Vortex Mixer. Incubated samples at 
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90-96oC for 10 minutes, protected from light.  
(4) Cooled the samples at the room temperature for 20 minutes, protected from 
light.  
(5) Centrifugalized the samples at 14,000 RPM with a bench-top centrifuge for 
30 seconds. Transferred 200 μl solution from each eppendorf to a 
pre-determined well of the 96-well microplate for ELISA plate reading with 
proper wavelength settings (excitation wavelength: 485 nm; emission 
wavelength: 590 nm).  
(6) Estimated BSA concentration of samples with unknown concentrations by 
using the standard curve plotted with the fluorescence values versus the 
concentrations of the BSA standard solutions.  
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Figure 2.10. The standard curve of the NanoOrange® protein assay. 
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In vitro Drug Release of Small-molecule 
Therapies from Matrix-type ES PLGA  
Particles 
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3.1 Experiment and Conditions of Matrix-type ES PLGA Nanoparticles 
Generated via a Single Capillary Nozzle  
     Theophylline, a bronchodilator with a narrow therapeutic window for symptom 
minimization of asthma, belongs to the methylxanthine group of the drugs. It is a 
hydrophilic compound and has been used to treat respiratory diseases, such as asthma 
and chronic obstructive pulmonary diseases, for decades [Kanakal et al., 2014; Oprea 
et al., 2012; Sundaran et al., 2013]. On the other hand, Budesonide is a hydrophobic 
small molecule for airway inflammation control and asthma attack prevention. It is an 
inhaled corticosteroid with high topical anti-inflammatory activity and hepatic 
first-pass metabolism, and is often used to prevent asthma attack and to treat 
inflammatory bowel disease [Gupta and Bhargava, 2006; Shendge and Sayyad, 2013]. 
According to former clinical studies, low dose Theophylline (THY) is an efficacious 
add-on therapy to Budesonide (BUD) for the treatment of asthma [Barnes, 2002], and 
they are chosen as the hydrophilic and the hydrophobic model drugs for our research 
to study the key influential factors for their sustained release from ES PLGA 
nanoparticles. The molecular structure and the selective physicochemical properties of 
Budesonide and Theophylline are summarized in Figure 3.1 [Bispo et al., 2002; Drug 
Bank Website].  
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Figure 3.1. Molecular structures and selective physiological properties of Budesonide and 
Theophylline.  
 
     In the following Section 3.2, two types of nanoparticles, the 70-80 nm PLGA 
(Mw: 7,000-17,000 g/mol, LA/GA: 50/50) particles and the 130-140 nm PLGA (Mw: 
24,000-38,000 g/mol, LA/GA: 50/50) particles, were produced by the single capillary 
ES technique. Key ES process parameters for generating PLGA particles with desired 
dimensions were determined by online measurement of particle size distributions with 
an electrospray close system connected to the SMPS. Particle morphology was also 
observed by SEM imaging. The key electrospray process parameters used for particle 
generation are summarized in Table 3.1-3.3 as follows.  
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Table 3.1. Process parameters of the single capillary ES for the generation of 70-80 nm matrix-type 
PLGA (Mw: 7K-17K g/mol, LA/GA: 50/50) particles to determine the optimized drug-to-polymer ratio 
for release profile characterization.  
 
 
 
 
 
 
 
Table 3.2. Process parameters of the single capillary ES for the generation of matrix-type PLGA (Mw: 
7K-17K g/mol, LA/GA: 50/50) particles to study the effect of the loaded mass of Theophylline on drug 
release behaviors of the particles (size: 70-80 nm) loaded with both Budesonide and Theophylline.  
 
 
 
5:10
10 mg/ml
7K-17K g/mol
5 cm
0.3 μl/min
300 μS/cm
Acetonitrile/DMSO 
(75/25)
F3
1:10
10 mg/ml
7K-17K g/mol
5 cm
0.3 μl/min
300 μS/cm
Acetonitrile/DMSO 
(75/25)
F1Formulation ID F2 F4
Spray solvent mixture
Acetonitrile/DMSO 
(75/25)
Acetonitrile/DMSO 
(75/25)
Electric conductivity of spray solvent 300 μS/cm 300 μS/cm
Feeding flowrate 0.3 μl/min 0.3 μl/min
Tip-to-collector (TTC) distance 5 cm 5 cm
PLGA molecular weight (LA/GA: 50/50) 7K-17K g/mol 7K-17K g/mol
PLGA concentration 10 mg/ml 10 mg/ml
Budesonide-to-PLGA mass ratio 2:10 8:10
1:101:101:10Budesonide-to-PLGA mass ratio
8:10
10 mg/ml
7K-17K g/mol
5 cm
0.3 μl/min
300 μS/cm
Acetonitrile/DMSO 
(75/25)
F7
1:10
10 mg/ml
7K-17K g/mol
5 cm
0.3 μl/min
300 μS/cm
Acetonitrile/DMSO 
(75/25)
F5Formulation ID F6
Spray solvent mixture
Acetonitrile/DMSO 
(75/25)
Electric conductivity of spray solvent 300 μS/cm
Feeding flowrate 0.3 μl/min
Tip-to-collector (TTC) distance 5 cm
PLGA molecular weight (LA/GA: 50/50) 7K-17K g/mol
PLGA concentration 10 mg/ml
Theophylline-to-PLGA mass ratio 5:10
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Table 3.3. Process parameters of the single capillary ES for the generation of matrix-type PLGA (Mw: 
24K-38K g/mol, LA/GA: 50/50) particles (size: 130-140 nm) to study the effect of drug combination 
on release behaviors of the particles.  
 
3.2 Results and Discussion  
3.2.1 Generation of PLGA Particles Smaller than 150 nm in Diameter  
     According to the ES process parameters in Section 3.1, two types of PLGAs 
with the same lactic-to-glycolic ratio but with different molecular weights (i.e., 
7,000-17,000 g/mol and 24,000-38,000 g/mol) were used to produce matrix-type 
PLGA nanoparticles in the sizes ranging between 70-80 nm and 130-140 nm via a 
single nozzle electrospray process. Size distributions of the as-produced PLGA 
nanoparticles are given in Figure 3.2. The geometric standard deviation (GSD) of 
synthesized nanoparticles was less than 1.40, suggesting excellent uniformity in sizes 
of the prepared PLGA particles. SEM imaging results shown in Figure 3.3 
demonstrate the morphology and also confirm the particle size/ size distributions of 
as-produced particles to be in the desired size ranges for subsequent research work. 
1:10-1:10Budesonide-to-PLGA mass ratio
1:10
10 mg/ml
24K-38K g/mol
5 cm
1.0 μl/min
120 μS/cm
Acetonitrile/DMSO 
(75/25)
F10
-
10 mg/ml
24K-38K g/mol
5 cm
1.0 μl/min
120 μS/cm
Acetonitrile/DMSO 
(75/25)
F8Formulation ID F9
Spray solvent mixture
Acetonitrile/DMSO 
(75/25)
Electric conductivity of spray solvent 120 μS/cm
Feeding flowrate 1.0 μl/min
Tip-to-collector (TTC) distance 5 cm
PLGA molecular weight (LA/GA: 50/50) 24K-38K g/mol
PLGA concentration 10 mg/ml
Theophylline-to-PLGA mass ratio 1:10
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These particles were then used to encapsulate drugs according to the process 
parameters listed in Table 3.1, Table 3.2 and Table 3.3 to become the formulations as 
F1-F10 for testing to learn their drug release behaviors in vitro.  
 
 
(A) 
 
(B) 
Figure 3.2. Size distributions of the matrix-type PLGA nanoparticles measured by SMPS: (A) 79.1 nm 
(GSD: 1.35) PLGA (Mw: 7K-17K g/mol, LA/GA: 50/50) particles, (B) 135.8 nm (GSD: 1.36) PLGA 
(Mw: 24K-38K g/mol, LA/GA: 50/50) particles.  
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(A)  
 
(B)  
Figure 3.3. SEM images of: (A) 70-80 nm matrix-type PLGA (Mw: 7K-17K g/mol, LA/GA: 50/50) 
particles, (B) 130-140 nm matrix-type PLGA (Mw: 24K-38K g/mol, LA/GA: 50/50) particles.  
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3.2.2 Determination of the Loaded Drug-to-PLGA Ratio for Budesonide and 
Theophylline  
     As the highest drug release rate is anticipated to be seen from particles with 
smaller size, the 70-80 nm matrix-type PLGA (Mw: 7,000-17,000, LA/GA: 50/50) 
particles were employed to determine the drug-to-polymer ratio of Budesonide and 
Theophylline that should be used throughout the research work in Chapter 3 and 
Chapter 4. For determination of the Budesonide-to-PLGA ratio, a single capillary 
electrospray process was employed to generate the 70-80 nm matrix-type PLGA 
particles composed of different Budesonide-to-PLGA concentration ratios (1:10, 2:10, 
5:10, and 8:10 as F1, F2, F3 and F4, respectively). In vitro drug release studies were 
then performed to determine the mass ratio of the encapsulated Budesonide to the 
polymer matrix based on the resultant release profiles shown in Figure 3.4. The 
slower Budesonide release rate observed from the data could be attributed to lower 
infusion rate of the media surrounding the particles, which eventually leaded to 
delayed drug dissolution and drug release. The 1:10 Budesonide-to-PLGA ratio was 
chosen also because particles generated with this drug-to-polymer ratio performed the 
sustained drug release behavior that allowed most of the encapsulated Budesonide to 
be released during the 102-hour drug release testing to minimize the impact of dose 
dumping. The 1:10 drug-to-polymer ratio also ensures that the released Budesonide 
can be accurately detected by HPLC, especially at the late stage of drug release when 
the amount of drug in the media is usually low.  
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Figure 3.4. In vitro drug release profiles of Budesonide from the 70-80 nm matrix-type ES PLGA (Mw: 
7K-17K g/mol, LA/GA: 50/50) particles encapsulating Budesonide in different drug-to-polymer mass 
ratios (formulations F1-F4).  
 
     Similar to Budesonide, the dose of Theophylline has also been determined via a 
series of drug release studies from 70-80 nm matrix-type PLGA (Mw: 7,000-17,000 
g/mol, LA/GA: 50/50) particles loaded with Theophylline in different mass ratios of 
Theophylline-to-PLGA. Meanwhile, a fixed amount of Budesonide 
(Budesonide-to-PLGA mass ratio: 1:10) was co-encapsulated with Theophylline to 
ensure that the resultant particle formulations could perform sustained release over 
both Budesonide and Theophylline. The results in Figure 3.5 show that the release 
rate of Theophylline was always fast and with insignificant difference regardless of 
the amount of loaded Theophylline. However, greater amount of Theophylline in the 
formulation promoted the release rate of Budesonide. Such a finding could be 
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explained by the greater spaces left behind by the fast dissolution and release of 
Theophylline after the influx of release media into the particles. Therefore, it was 
expected that Budesonide molecules, except for those loaded near the surface of the 
particles, encountered weaker resistance against diffusion, leading to a higher 
Budesonide drug release rate. Based on above discussions, the 1:10 
Theophylline-to-PLGA ratio was chosen for the following thesis work of Chapter 3 
and the most part of Chapter 4.  
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(A)  
 
(B)  
Figure 3.5. In vitro drug release profiles of (A) Budesonide and (B) Theophylline from the 70-80 nm 
matrix-type ES PLGA (Mw: 7K-17K g/mol, LA/GA: 50/50) particles loaded with both drugs.  
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3.2.3 Effects of Drug Combination on Release Behaviors  
     The key objective of this work is to explore the feasibility of achieving the 
sustained release for both hydrophobic and hydrophilic drugs when both are loaded in 
ES PLGA nanoparticles (both matrix-type and core-shell type particles). Therefore, it 
is crucial to probe into how a singular active ingredient in a single dosage formulation 
is released from the nanoparticulate PLGA drug carriers. The influence of each loaded 
drug compound on the drug release behaviors of the other when both of them are 
simultaneously encapsulated in the nanoparticles can thus be further studied. Herein, 
three different PLGA (Mw: 24,000-38,000 g/mol, LA/GA: 50/50) nano-particulate 
formulations (i.e., F8, F9 and F10; particle size: 130-140 nm) loaded with Budesonide, 
Theophylline, and the combination of Budesonide and Theophylline as shown in 
Figure 3.6 were produced. The resultant drug release profiles of Budesonide and 
Theophylline are displayed in Figure 3.7. It is observed that the Budesonide release 
rate of F8 was not significantly different from that of F10. However, the Theophylline 
release rate of F10 was much higher than that of F9. The above observations may be 
associated with the void space left behind by the released drug molecules. Due to the 
higher molecular weight of Budesonide (430.53 g/mol) than Theophylline (180.16 
g/mol), release of Budesonide created larger void spaces than release of Theophylline 
did in the polymer matrix. When Budesonide and Theophylline were co-encapsulated 
in the matrix-type PLGA particles, release of Budesonide promoted the Theophylline 
release via these larger void spaces and therefore accelerated its release rate by the 
enhanced infusion rate of the surrounding release media. Thus, Theophylline release 
rate was faster when co-encapsulated with Budesonide in PLGA nanoparticles than 
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the case when Theophylline was singly encapsulated in the same type of PLGA drug 
carrier. On the contrary, the void spaces created by the Theophylline drug release were 
smaller than those left behind by Budesonide drug release. That is why there was no 
significant difference between the Budesonide release rates of F8 and F10 from the 
perspective of void spaces in the polymer matrix. Figure 3.7 (C) indicates that over 
80% of the loaded Theophylline was released within the first 30 minutes of the 2-day 
drug release testing. More efforts need to be made to slow down the release rate of 
Theophylline from ES PLGA nanoparticles. Relevant work will be performed, and the 
resultant data will be presented and discussed in the following sections.  
 
 
Figure 3.6. The schematic diagram of the 130-140 nm matrix-type ES PLGA (Mw: 24K-38K g/mol, 
LA/GA: 50/50) particles loaded with Budesonide (B) and/ or Theophylline (T).  
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(A) Comparison of release profiles of Budesonide from F8 and F10.  
 
 
(B) Comparison of release profiles of Theophylline from F9 and F10.  
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(C) Release profiles of Budesonide and Theophylline from F10.  
Figure 3.7. In vitro drug release profiles of Budesonide (B) and Theophylline (T) from the 130-140 nm 
matrix-type ES PLGA (Mw: 24K-38K g/mol, LA/GA: 50/50) particles loaded with Budesonide (F8), 
Theophylline (F9) and the combination of Budesonide and Theophylline (F10). Duplicate testing with 
N=2.  
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3.3 Summary  
     Matrix-type PLGA nanoparticles (70-80 nm and 130-140 nm in diameter) were 
produced via the single capillary electrospray (ES) technique along with adequate 
process parameters determined by the close electrospray system through online 
measurement of particle size distributions. Two types of PLGAs with same LA/GA 
ratio (i.e., 50/50) but different molecular weights (i.e., 7,000-17000 g/mol and 
24,000-38,000 g/mol) were used for particle generation. In vitro drug release testing 
with the centrifugation method and the previously developed HPLC analytical 
methods were utilized to study release profiles of Budesonide and Theophylline from 
the 70-80 nm matrix-type PLGA (Mw: 7,000-17,000 g/mol; LA/GA: 50/50) particles 
with different drug-to-polymer ratios in order to determine the appropriate amount of 
model drugs to be loaded in the particles. By using the 130-140 nm PLGA (Mw: 
24,000-38,000 g/mol, LA/GA: 50/50) particles, Budesonide and/ or Theophylline 
were encapsulated in the particles to study how a model drug influenced release 
behaviors of the other when two model drugs were co-encapsulated in the matrix-type 
ES PLGA nanoparticles (i.e., F8, F9 and F10). The results suggest that Theophylline 
release rate was affected by Budesonide while the release rate of Budesonide was not 
significantly influenced by Theophylline when the two drugs were loaded in a single 
dosage formulation. The finding could be attributed to the sizes of the void spaces left 
behind by the released drug molecules. Considering the high Theophylline release rate 
from formulation F10, further efforts have to be made in order to apply the ES PLGA 
nanoparticles to extended release of both highly hydrophilic and hydrophobic active 
ingredients for fixed dose combination therapy. In the mean time, the results and the 
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conclusions obtained from F1-F10 also demonstrate that the methodology developed 
for particle generation and characterization of particle size distribution and in vitro 
drug release profiles were feasible and reliable for matrix-type PLGA nanoparticles. 
The same methodology is therefore applied to the subsequent thesis work to 
investigate the release profiles of small-molecule model drugs from the core-shell 
type PLGA nanoparticles produced by the coaxial dual capillary ES technique.  
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Chapter 4 
 
In vitro Drug Release of Small-molecule 
Therapies from Core-shell  
Type ES PLGA Particles 
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4.1 Experiment and Conditions of Core-shell Type ES PLGA Nanoparticles 
Generated via a Coaxial Dual Capillary Nozzle 
     Drug release from PLGA particles takes place via a combination of several 
mechanisms, including detachment of surface-bound drug molecules, drug diffusion 
through the polymer matrix and erosion of filling materials of the particles [Zarchi et 
al., 2015]. For matrix-type PLGA nanoparticles, a biphasic drug release profile, 
wherein there is an initial burst release, is commonly seen. The initial burst release is 
caused by the surface/ near-surface loading of loaded drugs and is usually much more 
severe for hydrophilic compounds, leading to potential safety concerns to patients and 
shorter duration for extended drug release [Almería et al., 2011]. To overcome the 
issue of the initial burst release of drugs, the coaxial dual capillary electrospray (ES) 
was proposed in literature and utilized in this research to encapsulate model drugs. 
Due to the capabilities of the dual capillary ES to generate drug-loaded PLGA 
particles with desired compositions of particle filling materials, loading configurations 
of drugs, and internal structures of particles, a systematic investigation by using the 
particle generation technique was performed to learn how these factors influence drug 
release behaviors. Key factors for extended release of Theophylline (the highly 
hydrophilic small-molecule model drug) and the combination of Theophylline and 
Budesonide (the highly hydrophobic small-molecule model drug) were also identified 
by looking into the resultant drug release profiles.  
     For the research purposes, PLGA particles with overall sizes ranging from 
380-440 nm (i.e., the 400-nm particles) and 880-1150 nm (i.e., the 1-μm particles) 
were generated for drug encapsulation in order to improve particle deposition in 
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alveolar regions of the lung for systemic drug delivery and to slowly release the active 
ingredients loaded in the particles. Similar to previous sections, ES process 
parameters to produce PLGA particles with dimensions within desired size ranges 
were determined by a close electrospray system connected with particle sizing 
instruments. Herein, two different particle sizers, the SMPS and the OPS, were 
utilized to size particles smaller and greater than 500 nm, respectively, according to 
their detectable particle size ranges (SMPS: 3 nm-700 nm; OPS: 100 nm-10 μm). 
Process parameters of the coaxial dual capillary electrospray (ES) for the thesis work 
of Chapter 4 are summarized in Table 4.1-4.8 as follows.  
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Table 4.1. Process parameters of the coaxial dual capillary ES for the generation of core-shell PLGA 
(core: Mw 54K-69K g/mol, LA/GA: 50/50; shell: Mw 24K-38K g/mol; LA/GA: 50/50) composite 
particles (particle size: 400 nm) loaded with Budesonide (BUD) and Theophylline (THY) in tested 
configurations (F11: Core loaded with Budesonide and Theophylline; F12: Core loaded with 
Budesonide, shell loaded with Theophylline; F13: Core loaded with Theophylline, shell loaded with 
Budesonide).  
 
 
 
 
 
 
 
Acetonitrile/DMSO 
(75/25)
Acetonitrile/DMSO 
(75/25)
Acetonitrile/DMSO 
(75/25)
Spray solvent mixture
8.08.08.0Tip-to-collector (TTC) distance (cm)
-1:10-THY:PLGA mass ratio
1:10--BUD:PLGA mass ratio
202020PLGA conc. (mg/ml)
24K-38K; 50/5024K-38K; 50/5024K-38K; 50/50PLGA (Mw; LA/GA)
2.52.52.5Feeding flowrate (μl/min)
303030Electric conductivity (μS/cm)
Outer 
solution
1:10-1:10THY:PLGA mass ratio
-1:101:10BUD:PLGA mass ratio
252525PLGA conc. (mg/ml)
54K-69K; 50/5054K-69K; 50/5054K-69K; 50/50PLGA (Mw; LA/GA)
0.50.50.5Feeding flowrate (μl/min)
303030Electric conductivity (μS/cm)
Inner 
solution
F13F12F11Formulation ID
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Table 4.2. Process parameters of the coaxial dual capillary ES for the generation of core-shell PLGA 
(core: Mw 50K-75K g/mol, LA/GA: 85/15; shell: Mw 24K-38K g/mol; LA/GA: 50/50) composite 
particles (particle size: 400 nm) loaded with Budesonide (BUD) and Theophylline (THY) in tested 
configurations (F14: Core loaded with Budesonide and Theophylline; F15: Core loaded with 
Budesonide, shell loaded with Theophylline; F16: Core loaded with Theophylline, shell loaded with 
Budesonide).  
 
 
 
 
 
 
 
Acetonitrile/DMSO 
(75/25)
Acetonitrile/DMSO 
(75/25)
Acetonitrile/DMSO 
(75/25)
Spray solvent mixture
8.08.08.0Tip-to-collector (TTC) distance (cm)
-1:10-THY:PLGA mass ratio
1:10--BUD:PLGA mass ratio
202020PLGA conc. (mg/ml)
24K-38K; 50/5024K-38K; 50/5024K-38K; 50/50PLGA (Mw; LA/GA)
2.52.52.5Feeding flowrate (μl/min)
303030Electric conductivity (μS/cm)
Outer 
solution
1:10-1:10THY:PLGA mass ratio
-1:101:10BUD:PLGA mass ratio
101010PLGA conc. (mg/ml)
50K-75K; 85/1550K-75K; 85/1550K-75K; 85/15PLGA (Mw; LA/GA)
0.50.50.5Feeding flowrate (μl/min)
303030Electric conductivity (μS/cm)
Inner 
solution
F16F15F14Formulation ID
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Table 4.3. Process parameters of the coaxial dual capillary ES for the generation of core-shell PLGA 
(core: Mw 50K-75K g/mol, LA/GA: 85/15; shell: Mw 50K-75K g/mol; LA/GA: 85/15) composite 
particles (particle size: 400 nm) loaded with Budesonide (BUD) and Theophylline (THY) in tested 
configurations (F17: Core loaded with Budesonide and Theophylline; F18: Core loaded with 
Budesonide, shell loaded with Theophylline; F19: Core loaded with Theophylline, shell loaded with 
Budesonide).  
 
 
 
 
 
 
 
Acetonitrile/DMSO 
(75/25)
Acetonitrile/DMSO 
(75/25)
Acetonitrile/DMSO 
(75/25)
Spray solvent mixture
8.08.08.0Tip-to-collector (TTC) distance (cm)
-1:10-THY:PLGA mass ratio
1:10--BUD:PLGA mass ratio
202020PLGA conc. (mg/ml)
50K-75K; 85/1550K-75K; 85/1550K-75K; 85/15PLGA (Mw; LA/GA)
2.52.52.5Feeding flowrate (μl/min)
303030Electric conductivity (μS/cm)
Outer 
solution
1:10-1:10THY:PLGA mass ratio
-1:101:10BUD:PLGA mass ratio
12.512.512.5PLGA conc. (mg/ml)
50K-75K; 85/1550K-75K; 85/1550K-75K; 85/15PLGA (Mw; LA/GA)
1.01.01.0Feeding flowrate (μl/min)
303030Electric conductivity (μS/cm)
Inner 
solution
F19F18F17Formulation ID
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Table 4.4. Process parameters of the coaxial dual capillary ES for the generation of core-shell PLGA 
(core: Mw 50K-75K g/mol, LA/GA: 85/15; shell: Mw 50K-75K g/mol; LA/GA: 85/15) particles 
(particle size: 400 nm) loaded with Theophylline (THY) in tested configurations (F20: Theophylline 
loaded in core; F21: Theophylline loaded in core and shell).   
 
 
 
 
 
 
 
Acetonitrile/DMSO 
(75/25)
Acetonitrile/DMSO 
(75/25)
Spray solvent mixture
8.08.0Tip-to-collector (TTC) distance (cm)
1:4-THY:PLGA mass ratio
--BUD:PLGA mass ratio
2020PLGA conc. (mg/ml)
50K-75K; 85/1550K-75K; 85/15PLGA (Mw; LA/GA)
2.52.5Feeding flowrate (μl/min)
3030Electric conductivity (μS/cm)
Outer 
solution
1:101:10THY:PLGA mass ratio
--BUD:PLGA mass ratio
12.512.5PLGA conc. (mg/ml)
50K-75K; 85/1550K-75K; 85/15PLGA (Mw; LA/GA)
1.01.0Feeding flowrate (μl/min)
3030Electric conductivity (μS/cm)
Inner 
solution
F21F20Formulation ID
 65 
 
 
 
 
 
 
 
 
Table 4.5. Process parameters of the coaxial dual capillary ES for the generation of core-shell 
Theophylline-loaded particles (particle size: 400-450 nm) composed of PLGA with various molecular 
weights and lactic-to-glycolic ratios. F20: PLGA (Mw: 50K-75K g/mol, LA/GA: 85/15), F22: PLGA 
(Mw: 7K-17K g/mol, LA/GA: 50/50), F23: PLGA (Mw: 24K-38K g/mol, LA/GA: 50/50).  
 
 
 
 
 
 
 
 
 
Acetonitrile/DMSO 
(75/25)
Acetonitrile/DMSO 
(75/25)
Acetonitrile/DMSO 
(75/25)
Spray solvent mixture
8.08.08.0Tip-to-collector (TTC) distance (cm)
---THY:PLGA mass ratio
---BUD:PLGA mass ratio
202020PLGA conc. (mg/ml)
24K-38K; 50/507K-17K; 50/5050K-75K; 85/15PLGA (Mw; LA/GA)
2.52.52.5Feeding flowrate (μl/min)
303030Electric conductivity (μS/cm)
Outer 
solution
1:101:101:10THY:PLGA mass ratio
---BUD:PLGA mass ratio
252512.5PLGA conc. (mg/ml)
24K-38K; 50/507K-17K; 50/5050K-75K; 85/15PLGA (Mw; LA/GA)
0.50.51.0Feeding flowrate (μl/min)
303030Electric conductivity (μS/cm)
Inner 
solution
F23F22F20Formulation ID
 66 
 
 
 
 
 
 
 
 
 
 
Table 4.6. Process parameters of the coaxial dual capillary ES for the generation of core-shell PLGA 
(Mw: 7K-17K g/mol, LA/GA: 50/50) particles with the same core sizes but different shell layer 
thicknesses to encapsulate Theophylline in the particle cores (F22: 400 nm particles with thinner shell 
thickness, F24: 1 μm particles with thicker shell thickness).  
 
 
 
 
 
 
 
Acetonitrile/DMSO 
(75/25)
Acetonitrile/DMSO 
(75/25)
Spray solvent mixture
8.08.0Tip-to-collector (TTC) distance (cm)
--THY:PLGA mass ratio
--BUD:PLGA mass ratio
154.6420PLGA conc. (mg/ml)
7K-17K; 50/507K-17K; 50/50PLGA (Mw; LA/GA)
2.52.5Feeding flowrate (μl/min)
3030Electric conductivity (μS/cm)
Outer 
solution
1:101:10THY:PLGA mass ratio
--BUD:PLGA mass ratio
2525PLGA conc. (mg/ml)
7K-17K; 50/507K-17K; 50/50PLGA (Mw; LA/GA)
0.50.5Feeding flowrate (μl/min)
3030Electric conductivity (μS/cm)
Inner 
solution
F24F22Formulation ID
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Table 4.7. Process parameters of the coaxial dual capillary ES for the generation of core-shell PLGA 
(Mw: 7K-17K g/mol, LA/GA: 50/50) particles (particle size: 1 μm) loaded with Theophylline and/ or 
Budesonide in the cores of particles (F24: Core loaded with Theophylline; F25: Core loaded with 
Budesonide and Theophylline).  
 
 
 
 
 
 
 
Acetonitrile/DMSO 
(75/25)
Acetonitrile/DMSO 
(75/25)
Spray solvent mixture
8.08.0Tip-to-collector (TTC) distance (cm)
--THY:PLGA mass ratio
--BUD:PLGA mass ratio
154.64154.64PLGA conc. (mg/ml)
7K-17K; 50/507K-17K; 50/50PLGA (Mw; LA/GA)
2.52.5Feeding flowrate (μl/min)
3030Electric conductivity (μS/cm)
Outer 
solution
1:101:10THY:PLGA mass ratio
1:10-BUD:PLGA mass ratio
2525PLGA conc. (mg/ml)
7K-17K; 50/507K-17K; 50/50PLGA (Mw; LA/GA)
0.50.5Feeding flowrate (μl/min)
3030Electric conductivity (μS/cm)
Inner 
solution
F25F24Formulation ID
 68 
 
 
 
 
 
 
 
 
 
 
Table 4.8. Process parameters of the coaxial dual capillary ES for the generation of core-shell PLGA 
(Mw: 50K-75K g/mol, LA/GA: 85/15) composite particles (particle size: 400 nm) encapsulating 
Budesonide and Theophylline in particle core with different THY-to-PLGA mass ratios.  
 
4.2 Results and Discussion  
4.2.1 Effects of Drug Loading Locations of Co-encapsulated Budesonide and 
Theophylline in Particles on Drug Release  
     Composite particles (particle size: 400 nm) with three loading conditions (i.e., 
both Budesonide and Theophylline loaded in the core; Budesonide loaded in the core 
and Theophylline loaded in the shell; Theophylline loaded in the core and Budesonide 
loaded in the shell) were produced via the dual capillary ES. Release profiles of 
Acetonitrile/DMSO 
(75/25)
Acetonitrile/DMSO 
(75/25)
Spray solvent mixture
8.08.0Tip-to-collector (TTC) distance (cm)
--THY:PLGA mass ratio
--BUD:PLGA mass ratio
2020PLGA conc. (mg/ml)
50K-75K; 85/1550K-75K; 85/15PLGA (Mw; LA/GA)
2.52.5Feeding flowrate (μl/min)
3030Electric conductivity (μS/cm)
Outer 
solution
1:201:10THY:PLGA mass ratio
1:101:10BUD:PLGA mass ratio
12.512.5PLGA conc. (mg/ml)
50K-75K; 85/1550K-75K; 85/15PLGA (Mw; LA/GA)
1.01.0Feeding flowrate (μl/min)
3030Electric conductivity (μS/cm)
Inner 
solution
F26F17Formulation ID
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Budesonide and Theophylline were investigated when both loaded in PLGA 
composite particles for fixed-dose combination therapy. Three PLGA polymers, 
PLGA (Mw: 24,000-38,000 g/mol, LA/GA: 50/50), PLGA (Mw: 54,000-69,000 g/mol, 
LA/GA: 50/50) and PLGA (Mw: 50,000-75,000 g/mol, LA/GA: 85/15) were used to 
produce three types of composite drug-loaded nano-carriers with ES parameters listed 
in Table 4.1, Table 4.2 and Table 4.3 to encapsulate Budesonide and Theophylline in 
tested configurations as shown in Figure 4.1.  
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Figure 4.1. The schematic diagrams of the 400-nm Budesonide (B)-Theophylline (T) loaded core-shell 
type ES PLGA composite particles in tested drug loading configurations. (A) core: Mw 54K-69K g/mol, 
LA/GA: 50/50; shell: Mw 24K-38K g/mol, LA/GA: 50/50, (B) core: Mw 50K-75K g/mol, LA/GA: 
85/15, shell: Mw 24K-38K g/mol, LA/GA: 50/50, (C) core: Mw 50K-75K g/mol, LA/GA: 85/15; shell: 
Mw 50K-75K g/mol, LA/GA: 85/15.  
 
     With the drug release testing procedures and the HPLC analytical methods of 
Budesonide and Theophylline developed in Chapter 2, in vitro drug release profiles of 
F11, F12 and F13 are given in Figure 4.2. The configuration effect (i.e., the loading 
locations of the drugs in the particles) was observed for the case of Budesonide as the 
release profiles shown in Figure 4.2 (A). With the shortest distance for the influx of 
the release media and the drug diffusion in the polymer matrix, Budesonide release 
rate of F13 was highest compared to that of F11 and F12 due to the fastest drug 
dissolution and the thinnest diffusion barrier thickness. A significant difference in 
Budesonide release rate was also seen for the cases when it was loaded in the particle 
core (i.e., F11 and F12). The finding may be explained by the void spaces left behind 
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after the release of Theophylline loaded in the particle shell, allowing faster infusion 
of the release media to the cores of the particles for drug dissolution and creating less 
hindrance for drug release. On the other hand, Theophylline release rates were similar 
among F11, F12 and F13. Due to the high aqueous solubility and the large diffusion 
coefficient, release of the core-loaded Theophylline through the void spaces resulted 
from the released Budesonide originally loaded in the shell (i.e., F13) was as fast as 
the case when Theophylline was loaded in the particle shell (i.e., F12). Compared to 
F10, Theophylline release rate was not suppressed by drug carriers with larger particle 
size, unique core-shell structure, and filling material with higher molecular weight 
(i.e., F11). Different PLGA materials were thus tested for greater effectiveness of 
sustained release of Theophylline.  
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(A)  
 
(B)  
Figure 4.2. Release profiles of Budesonide (B) and Theophylline (T) from PLGA (core: Mw 54K-69K 
g/mol, LA/GA: 50/50; shell: Mw 24K-38K g/mol, LA/GA: 50/50) composite particles (particle size: 
400 nm) with both drugs loaded in tested configurations: (A) release profiles of Budesonide, (B) 
release profiles of Theophylline. Duplicate testing with N=2.  
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     PLGA (Mw: 50,000-75,000 g/mol, LA/GA: 85/15) was expected to be with 
slower polymer degradation rate compared to PLGA (Mw: 54,000-69,000 g/mol, 
LA/GA: 50/50) because of the higher lactic-to-glycolic ratio. Therefore, the polymer 
could provide greater capabilities for slow release of Theophylline [Makadia and 
Siegel, 2011]. Accordingly, the 400-nm PLGA (core: Mw 50,000-75,000 g/mol, 
LA/GA: 85/15; shell: Mw 24,000-38,000 g/mol, LA/GA: 50/50) composite particles 
(i.e., F14, F15 and F16) and the 400-nm PLGA (core: Mw 50,000-75,000 g/mol, 
LA/GA: 85/15; shell: Mw 50,000-75,000 g/mol, LA/GA: 85/15) composite particles 
(i.e., F17, F18 and F19) were generated by ES process parameters listed in Table 4.2 
and Table 4.3, respectively. The schematic diagrams of the as-produced 
nano-particulate formulations are given in Figure 4.1 (B) and Figure (C), respectively, 
to illustrate detailed drug loading locations of Budesonide and Theophylline in the 
tested particles. The resultant release profiles of F14 (EE% of Budesonide: 88.1%, 
EE% of Theophylline: 90.2%), F15 (EE% of Budesonide: 93.6%, EE% of 
Theophylline: 92.2%) and F16 (EE% of Budesonide: 96.9%, EE% of Theophylline: 
97.4%) are displayed in Figure 4.3. Similar to the findings shown in Figure 4.2 (A), 
the release rate of Budesonide was also determined by its loading locations in the 
core-shell PLGA nanoparticles. The F16 released Budesonide in the fastest release 
rate since the majority of Budesonide molecules were loaded in the particle shell. 
Compared to the case when Budesonide and Theophylline were both loaded in the 
cores of the particles (i.e., F14), the shell-loaded Theophylline promoted the release 
rate of core-loaded Budesonide (i.e., F15). On the other hand, the tested PLGA 
composite drug nano-carrier (particle size: 400 nm) was conducive to slow down the 
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release rate of Theophylline. In Figure 4.3 (B), Theophylline release rate from F14 
was significantly slower than the cases of Theophylline release from F15 and F16 
with close to 70% of the encapsulated Theophylline was released during the first hour 
of the 2-day release testing. Compared to F14, formulation F15 released Theophylline 
in a higher drug release rate because Theophylline was encapsulated in the shell of 
particles. The Theophylline release rate from F16 was almost identical with that from 
F15 because the release rate of the core-loaded Theophylline in F16 was boosted by 
the shell-loaded Budesonide. The reasons behind the finding have been discussed for 
the discussions of Theophylline release profiles from F12 and F13 and would not be 
addressed herein again.  
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(A)  
 
(B)  
Figure 4.3. Release profiles of Budesonide (B) and Theophylline (T) from PLGA (core: Mw 50K-75K 
g/mol, LA/GA: 85/15; shell: Mw 24K-38K g/mol, LA/GA: 50/50) composite particles (particle size: 
400 nm) with both drugs loaded in tested configurations: (A) release profiles of Budesonide, (B) 
release profiles of Theophylline. Duplicate testing with N=2.  
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     To further slow down the release rate of Theophylline from the 400-nm PLGA 
particles, especially for the drug loading configuration when Budesonide and 
Theophylline were both encapsulated in the core of the particles, the core-shell 
particles composed of PLGA (Mw: 50,000-75,000 g/mol, LA/GA: 85/15) in core and 
shell of the particles were produced via the coaxial dual capillary ES process for drug 
encapsulation. The resultant drug release profiles are depicted in Figure 4.4. Similar 
to our previous observations in Figure 4.2 (A) and Figure 4.3 (A), release rate of 
Budesonide from the particles with drugs loaded in the TB configuration (i.e., 
Theophylline loaded in core, Budesonide loaded in shell) was faster than that from the 
particles with drugs loaded in the BT configuration (i.e., Budesonide loaded in core, 
Theophylline loaded in shell) due to the configuration effect. However, Figure 4.4 (A) 
displays higher Budesonide release rate in F17 than F18, implying high porosity of 
electrosprayed PLGA (Mw: 50,000 g/mol, LA/GA: 85/15), allowing fast infusion of 
the release media for fast drug dissolution and drug release. Such an assumption will 
be proven later via Brunauer-Emmett-Teller (BET) Surface Area Analysis on 400-nm 
drug-loaded PLGA particles. Figure 4.4 (B) shows equally fast Theophyllind release 
rates of F17, F18 and F19, suggesting the infusion rate of the release media into the 
composite nanoparticles was extremely fast possibly due to the high porosity of the 
particles.  
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(A)  
 
(B)  
Figure 4.4. Release profiles of Budesonide (B) and Theophylline (T) from PLGA (core: Mw 50K-75K 
g/mol, LA/GA: 85/15; shell: Mw 50K-75K g/mol, LA/GA: 85/15) composite particles (particle size: 
400 nm) with both drugs loaded in tested configurations: (A) release profiles of Budesonide, (B) 
release profiles of Theophylline. Duplicate testing with N=2.  
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     Taken all together, in vitro drug release behaviors of Budesonide and 
Theophylline from Budesonide-Theophylline loaded 400-nm PLGA composite 
particles may be explained by the drug loading locations along with the void spaces in 
the particle shell left behind by the release of the shell-loaded drug molecules for 
particles composed of PLGA (Mw: 50,000-75,000 g/mol, LA/GA: 85/15) and PLGA 
(Mw: 24,000-38,000 g/mol, LA/GA: 50/50) in core and shell, respectively. Size 
distributions and SEM images of F14, F15 and F16 are shown in Figure 4.5 and 
Figure 4.6, respectively. The B+T configuration (i.e., Budesonide and Theophylline 
both loaded in particle core) may be the most capable one to slow down the release 
rate of Theophylline. However, release behaviors of Budesonide and Theophylline 
from the 400-nm composite nano-carriers shown in Figure 4.1 (A) and 4.1 (C) may 
not be explained perfectly. Therefore, effects of particle filling materials on drug 
release behaviors of Budesonide and Theophylline need to be studied. Due to the 
challenges of Theophylline slow release observed from release profiles of F11-F19, 
we first concentrated on Theophylline release from core-shell ES PLGA particles to 
determine the key factors influencing Theophylline release rate and to learn how to 
control it. Since the drug loading locations have been proven not to be fully capable of 
slowing down release rate of Theophylline from Budesonide-Theophylline loaded 
PLGA composite nanoparticles and not to be sufficient to provide a simplified theory 
to support the observed findings, the material effect and the particle shell layer 
thickness effect were subsequently investigated in the following sections for the 
extended release of Theophylline. Budesonide were then encapsulated together with 
Theophylline in the PLGA drug carriers capable of suppressing Theophylline release 
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rates to provide formulations that were able to accomplish extended release of both 
Budesonide and Theophylline simultaneously.  
 
 
Figure 4.5. Size distributions of F14, F15 and F16 core-shell PLGA nanoparticles (particle size: 400 
nm, GSD: 1.40) measured by SMPS. 
 
 
(A)  
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(B)  
 
(C)  
Figure 4.6. SEM images of 400-nm core-shell PLGA nanoparticles with tested drug loading 
configurations: (A) F14: core loaded with Budesonide and Theophylline, (B) F15: core loaded with 
Budesonide, shell loaded with Theophylline, (C) F16: core loaded with Theophylline, shell loaded with 
Budesonide.  
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4.2.2 Effects of Loading Locations of Singly Encapsulated Theophylline in 
Particles on Drug Release 
     To study the release of Theophylline from core-shell PLGA particles, we first 
loaded Theophylline in the particle cores only (F20) and in both particle cores and 
particle shells (F21) with ES process parameters listed in Table 4.4. The PLGA 
polymer (Mw: 50,000-75,000 g/mol, LA/GA: 85/15) was used as the filler for particle 
cores and shells. The schematic diagrams of the as-produced nanoparticles are given 
in Figure 4.7 to illustrate the tested Theophylline loading configurations in the 
particles. Due to the similar ES process parameters of the outer solutions, size 
distributions of F20 and F21 were alike and shown in Figure 4.8. SEM images of F20 
and F21 are given in Figure 4.9. The above SMPS data and SEM images demonstrate 
the excellent morphology and uniform size distributions of F20 and F21.  
 
 
Figure 4.7. The schematic diagrams of the 400-nm Theophylline (T) loaded core-shell type ES PLGA 
(core and shell: Mw 50K-75K g/mol, LA/GA: 85/15) composite particles in tested drug loading 
configurations.  
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Figure 4.8. Size distributions of F20 and F21 core-shell PLGA particles (particle size: 400 nm, GSD: 
1.45) measured by SMPS.  
 
 
(A)  
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(B)  
Figure 4.9. SEM images of the 400-nm core-shell PLGA particles with tested Theophylline loading 
configurations: (A) F20: Theophylline loaded in the cores, (B) F21: Theophylline loaded in the cores 
and the shells.  
 
     Figure 4.10 shows the resultant release profiles of Theophylline from F20 
(EE% of Theophylline: 88.1%) and F21 (EE% of Theophylline: 95.1%). The data 
evidences that the release rate of Theophylline was increased in the case with 
Theophylline loaded in both particle cores and shells (F21) compared with the case 
when Theophylline was loaded in the particle core (F20). The higher Theophylline 
release rate of F21 was associated with the shorter distance in the core-shell-loaded 
particles for drug release. The release profiles in Figure 4.10 also suggest that the 
PLGA formulations prepared under both cases were incapable of effectively slow 
down the release rate of Theophylline. Approximately 85% of encapsulated 
Theophylline was released within the 1st hour even in the case when Theophylline 
 84 
was only loaded in the particle cores (i.e., F20). The above finding might be also 
attributed to the less affinity between Theophylline and the polymer filler [Almería et 
al., 2011].  
 
 
Figure 4.10. Release profiles of Theophylline (T) from PLGA (core: Mw 50K-75K g/mol, LA/GA: 
85/15; shell: Mw 50K-75K g/mol, LA/GA: 85/15) composite nanoparticles (particle size: 400 nm): (A) 
Theophylline loaded in the cores, (B) Theophylline loaded in the cores and the shells. Duplicate testing 
with N=2.  
 
4.2.3 Effects of Particle Filling Materials on Theophylline and/ or Budesonide 
Drug Release  
     To lessen the extent of initial burst release and to decrease the release rate of 
Theophylline from core-shell composite particles, three types PLGA polymers were 
applied to produce composites loaded with Theophylline in particle core. As shown in 
Figure 4.11, three particle formulations (with the size: 400-450 nm) were composed 
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of PLGA polymers (Mw: 7,000-17,000 g/mol, LA/GA: 50/50; Mw: 24,000-38,000 
g/mol, LA/GA: 50/50; and Mw: 50,000-75,000 g/mol, LA/GA: 85/15). Drug 
encapsulation efficiencies (EE%) of formulation F20, F22 and F23 were 88.1%, 
94.4% and 87.7%, respectively. The size distribution data and SEM images of the 
as-produced nanoparticles are shown in Figure 4.12 and Figure 4.13. Because the 
same feeding flowrate, electric conductivity and the polymer filling material and its 
concentration of the outer spray solution were employed to generate formulations 
F14-F16 and F23, the size distribution of F23 was almost identical with that of 
F14-F16 and may thus be referred to Figure 4.5. The resultant release profiles of 
Theophylline from prepared PLGA composites are given in Figure 4.14. Slow release 
rates of Theophylline were observed when it was encapsulated in particles composed 
of the PLGA polymer having lower lactic-to-glycolic ratio (i.e., F22 and F23). The 
above observation confirms the conclusion from literature that great affinity between 
drug and polymer filler could reduce the release rate of a hydrophilic pharmacologic 
agent from PLGA particles [Shi et al., 2008; Almería et al., 2011; Cao et al., 2014; 
Pereira et al., 2015]. It was interesting to notice that the release rate of Theophylline 
could be further reduced when Theophylline was encapsulated in particles composed 
of the PLGA polymer with a lactic-to-glycolic ratio of 50:50 but having low 
molecular weight (7,000-17,000 g/mol) (i.e., formulation F22). The above finding 
might be explained by the fact that the infusion of release media was impeded by the 
lower surface porosity and the smaller pore size in the particle matrix composed of 
PLGA polymers of low molecular weights (BET surface areas of formulations F20 
and F22: 3.7056 ± 0.1419 m²/g and 0.6801 ± 0.0658 m²/g, respectively; median pore 
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width of F20 and F22: 10.934 Å and 7.909 Å, respectively). The above observation 
implies that, in addition to the LA/GA ratio, the molecular weight of PLGA polymers 
could be a critical factor for the sustained release of Theophylline from PLGA 
particles.  
 
 
 
Figure 4.11. The schematic diagrams of Theophylline (T)-loaded ES core-shell PLGA composite 
particles (particle size: 400-450 nm) composed of PLGA (Mw: 50K-75K g/mol, LA/GA: 85/15), PLGA 
(Mw: 7K-17K g/mol, LA/GA: 50/50) and PLGA (Mw: 24K-38K g/mol, LA/GA: 50/50).  
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(A)  
 
(B)  
Figure 4.12. (A) Size distribution and (B) the SEM image of formulation F22 core-shell PLGA 
particles (particle size: 429.4 nm, GSD: 1.50) measured by SMPS.  
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Figure 4.13. The SEM image of formulation F23 core-shell PLGA particles (particle size: 400 nm) 
 
 
Figure 4.14. In vitro drug release profiles of Theophylline (T) from the core regions of the 
nanoparticles composed of PLGA with various molecular weights and lactic-to-glycolic ratios (particle 
size: 400-450 nm). F20: PLGA (Mw: 50K-75K g/mol, LA/GA: 85/15), F22: PLGA (Mw: 7K-17K 
g/mol, LA/GA: 50/50), F23: PLGA (Mw: 24K-38K g/mol, LA/GA: 50/50). Duplicate testing with 
N=2.  
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     Release profiles of Budesonide and Theophylline from the 400-nm PLGA 
composite particles given in Section 4.2.1 also allow us to compare drug release 
behaviors of Budesonide and Theophylline from Budesonide-Theophylline loaded 
core-shell PLGA composite nanoparticles composed of different filling materials in 
core or shell of a single particle formulation. Relying on the conclusions just made 
according to Theophylline release profiles of formulations F20-F23 shown in Figure 
4.14, drug release behaviors of selected Budesonide-Theophylline loaded particle 
formulations with the same drug loading configuration in Section 4.2.1 may be 
discussed as below. Figure 4.15 depicts release profiles of Budesonide and 
Theophylline, both loaded in particle cores, from formulations F14 and F17. Due to 
greater total surface area of PLGA (Mw: 50,000-75,000 g/mol, LA/GA: 85/15) than 
PLGA (Mw: 24,000-38,000 g/mol, LA/GA: 50/50), the infusion rate of the 
surrounding release media through the particle shell layer into the particle core was 
higher for the case of formulation F17 than formulation F14. Budesonide loaded in 
the cores of formulation F17 was dissolved by the infused release media earlier than 
that loaded in the cores of formulation F14 for drug release. During drug release, the 
shell layers of F17 provided lesser resistance due to its greater porosity than 
formulation F14. In the end, release rates of both Budesonide and Theophylline were 
higher from formulation F17 than F14.  
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(A)  
 
(B)  
Figure 4.15. Release profiles of (A) Budesonide and (B) Theophylline from the core regions of PLGA 
nanoparticles composed of different polymer compositions. Formulation F14: PLGA (Mw 50K-75K 
g/mol, LA/GA: 85/15) in the cores, PLGA (Mw 24K-38K g/mol, LA/GA: 50/50) in the shells; 
formulation F17: PLGA (Mw 50K-75K g/mol, LA/GA: 85/15) in both cores and shells. Duplicate 
testing with N=2.  
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     Release profiles of Budesonide and Theophylline from formulations F15 and 
F18 are given in Figure 4.16. In both cases, Budesonide and Theophylline were 
encapsulated in core regions and shell regions of PLGA particles (particle size: 400 
nm), respectively. Though the infusion rate of release media through the shell layer of 
F18 was greater than that of F15, the resultant Theophylline release rates were 
without too much difference because Theophylline was loaded in the cores of both 
particle formulations. In addition, Theophylline is a highly hydrophilic drug 
compound with great aqueous solubility. Therefore, release rates from formulations 
F15 and F18 were both extremely high due to the fast dissolution of Theophylline. 
However, a significant difference in the Budesonide release rate was observed 
between formulations F15 and F18. The particle shell of formulation F15 was 
composed of PLGA (Mw: 24,000-38,000 g/mol, LA/GA: 50/50) with smaller pore 
size compared to the filling material, i.e., PLGA (Mw: 50,000-75,000 g/mol, LA/GA: 
85/15), of the particle shell of formulation F18. Theophylline release from 
formulation F15 thus caused greater structural disruption on the filling material of the 
particle shells, leading to greater infusion of the release media into the particle cores 
and less resistance of diffusion for Budesonide. As a result, Budesonide was released 
more rapidly when it was loaded in the cores of formulation F15 compared to the case 
when it was loaded in cores of the formulation F18.  
 
 92 
 
(A)  
 
(B)  
Figure 4.16. Release profiles of (A) core-loaded Budesonide (B) and (B) shell-loaded Theophylline (T) 
from the 400-nm core-shell PLGA particles composed of different polymer compositions. Formulation 
F15: PLGA (Mw 50K-75K g/mol, LA/GA: 85/15) in particle cores, PLGA (Mw 24K-38K g/mol, 
LA/GA: 50/50) in particle shells; formulation F18: PLGA (Mw 50K-75K g/mol, LA/GA: 85/15) in 
both particle cores and shells. Duplicate testing with N=2.  
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     Figure 4.17 shows the release profiles of Budesonide and Theophylline from 
Budesonide-Theophylline loaded composite PLGA particle formulations. Herein, 
Theophylline and Budesonide were loaded in particle cores and shells, respectively. 
Fillers of the particle cores were PLGA (Mw: 50,000-75,000 g/mol, LA/GA: 85/15) 
for both formulations F16 and F19. Fillers of the particle shells were PLGA (Mw: 
24,000-38,000 g/mol, LA/GA: 50/50) and PLGA (Mw: 50,000-75,000 g/mol, LA/GA: 
85/15) for formulations F16 and F19, respectively. Though the infusion rate of release 
media through the shell layer of F19 was greater than that through the shell layer of 
F16, faster release rate of Budesonide from formulation F19 than F16 was not 
observed as expected. The finding implies that other factors might have offset the 
effects of the infusion of release media on drug release, which may be attributed to the 
void spaces in the particle shells created by the release of shell-loaded Budesonide. 
Because the molecular weight of Budesonide (430.53 g/mol) is larger than that of 
Theophylline (180.16 g/mol), larger spaces were left behind in the polymer matrix 
after the release of Budesonide. The void spaces resulted in greater material structural 
disruption in the shell of formulation F16 than that of F19 because the shells of F16 
was composed of PLGA (Mw: 24,000-38,000 g/mol, LA/GA: 50/50) with smaller 
pore size, which further led to greater influx of the release media for the dissolution 
and release of Budesonide loaded in particle shells. The extent of material structural 
disruption in the shell caused by the release of shell-loaded Budesonide also affected 
the release rate of the core-loaded Theophylline. That is why the Theophylline release 
rate of formulation F16 was increased to be equally as rapid as that of formulation 
F19 even though the shells of F19 was composed of the filler (i.e., PLGA: Mw 
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50,000-75,000 g/mol, LA/GA: 85/15) with larger surface porosity and pore size than 
the filler used to constitute the shells of formulation F16.  
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(A)  
 
 
(B)  
Figure 4.17. Release profiles of (A) shell-loaded Budesonide (B) and (B) core-loaded Theophylline (T) 
from PLGA nanoparticles composed of different polymer compositions. Formulation F16: PLGA (Mw 
50K-75K g/mol, LA/GA: 85/15) in core, PLGA (Mw 24K-38K g/mol, LA/GA: 50/50) in shell; 
formulation F19: PLGA (Mw 50K-75K g/mol, LA/GA: 85/15) in both core and shell. Duplicate testing 
with N=2. 
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4.2.4 Effects of Particle Shell Layer Thickness on Theophylline Drug Release  
     According to the results and discussions addressed from Section 4.2.1 to 4.2.3, 
drug release of Budesonide-Theophylline loaded core-shell PLGA particle composites 
(particle size: 400-450 nm) was affected by the drug loading locations, the void 
spaces left behind by the drug loaded in particle shell, and the surface porosity and 
pore size of the particle filling materials. Through the release profile studies on 
formulations F20, F22 and F23, the slowest Theophylline release rate was achieved 
by formulation F22, and the surface porosity and the pore size of the ES nanoparticles 
were correlated with the molecular weight of PLGA. The formulation F22 released 
Theophylline in the slowest extended release fashion among the formulations that 
have been tested so far in Chapter 4 (i.e., formulations F11-F23), which further 
emphasizes the PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 50/50) was the most 
capable particle filler for the sustained release of Theophylline.  
     To investigate the possibility of more reduction on the release rate of 
Theophylline, composite particles with similar cores but thicker shell thicknesses (i.e., 
F24) were produced with the ES process parameters listed in Table 4.6. In this part of 
investigation, PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 50/50) was used as the filler 
to encapsulate Theophylline in the cores of the prepared particles. By employing the 
inner solution with the same feeding flowrate, electric conductivity and polymer 
concentration, core dimensions of formulations F22 and F24 were similar. With the 
increased PLGA concentration in the outer solution during the coaxial dual capillary 
ES process, F24 (i.e., particles with greater shell layer thickness than F22) was 
produced with the SEM image and the size distributions characterized by OPS shown 
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in Figure 4.18. Given the known mass ratio of PLGA in particle core and shell for F22 
and F24 and measured overall particle diameters, the core dimensions may be 
estimated via the mass conservation. The estimated core diameters of F22 and F24 
were both 250 nm. Accordingly, the estimated shell layer thicknesses of F22 and F24 
were 90 nm and 360 nm, respectively. Due to the increased PLGA shell thickness, 
particle size of F24 (i.e., 1 μm) was larger than that of F22 (i.e., 430 nm). The 
schematic diagram of formulations F22 (EE%: 94.44%) and F24 (EE%: 90.0%) along 
with their resultant Theophylline release profiles are given in Figure 4.19 (A) and (B), 
respectively. It is evidenced that a further decrease of Theophylline release rate was 
accomplished by increasing the thickness of PLGA shell. The above observation is 
attributed to the extra time required for the release medium infusion into the particle 
core and the diffusion of Theophylline through the polymer filling matrix. The above 
finding suggests that particle shell layer thickness is critical for the slow release of 
Theophylline with PLGA particulate drug carriers no greater than 1 μm in diameter. 
Encapsulation of Theophylline in the core of lower–molecular-weight PLGA particles 
with greater shell thickness is an effective strategy to reduce the release rate of 
Theophylline and may also be applied to co-encapsulate Budesonide and 
Theophylline for the extended release of both drugs. Relevant research was performed 
in the following section to prove such a proposed concept.  
 
 98 
 
(A)  
 
Particle Size Distribution Measured by OPS
0
2000
4000
6000
8000
10000
12000
14000
30
0-
37
4
37
4-
46
5
46
5-
57
9
57
9-
72
1
72
1-
89
7
89
7-
11
17
11
17
-1
39
1
13
91
-1
73
2
17
32
-2
15
6
21
56
-2
68
5
26
85
-3
34
3
33
43
-4
16
2
41
62
-5
18
2
51
82
-6
45
1
64
51
-8
03
1
80
31
-1
00
00
Particle Size (μm)
dN
/ 
dL
og
 D
p 
(#
/ 
cm
3)
 
(B)  
Figure 4.18. (A) The SEM image and (B) the particle size distribution measured by the OPS of the 
1-μm core-shell PLGA (Mw: 7K-17K g/mol, LA/GA: 50/50 in core and shell) particles loaded with 
Theophylline in the particle cores (i.e., F24).  
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(A)  
 
(B)  
Figure 4.19. (A) The schematic diagrams and (B) the in vitro core-loaded Theophylline (T) release 
profiles of formulations F22 and F24 composed of PLGA (Mw: 7K-17K g/mol, LA/GA: 50/50) in both 
core and shell with the same core diameters but different shell thicknesses. Duplicate testing with N=2.  
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4.2.5 Effects of drug combination on release behaviors  
     To validate the sustained release of both model drugs from particles, we 
produced core-shell PLGA composite particles (Mw 7,000-17,000 g/mol and LA/GA: 
50/50) with the particle diameter of 1 μm by using the ES process parameters 
consolidated in Table 4.7 to encapsulate both Budesonide and Theophylline in the 
core of particles (i.e., formulation F25). Schematic diagrams of formulations F24 and 
F25 are displayed in Figure 4.20 (A) to illustrate the differences of the two 
formulations studied to compare their drug release behaviors. Figure 4.20 (B) depicts 
the release profiles of Theophylline from formulations F24 and F25. No significant 
difference was observed, evidencing that the release rate of Theophylline was not 
influenced by the presence of Budesonide when both drugs were co-encapsulated in 
the core of the 1-μm PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 50/50) core-shell 
particles. In this case, the void spaces left behind after the release of Budesonide did 
not significantly increase the release rate of Theophylline. The reason could be 
attributed to the high aqueous solubility of Theophylline, which is associated with the 
rapid drug dissolution of Theophylline in PBS. Thus, the release of Theophylline in 
this case was initiated earlier than that of Budesonide, and the release of Budesonide 
had limited impact on the release of Theophylline when both drugs were loaded in 
core of the 1-μm particles composed of PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 
50/50). On the other hand, formulation F25 also released the core-loaded Budesonide 
in a controlled fashion. Release profiles of both Budesonide and Theophylline from 
F25 (EE% of Budesonide: 94.9%, EE% of Theophylline: 92.1%) are given in Figure 
4.20 (C) as the finalized fixed-combined particle formulation in this dissertation work 
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for extended release of both Budesonide and Theophylline from a single dosage 
formulation. The formulation F25 utilized the same PLGA particle drug carrier for 
drug encapsulation in the core. Therefore, its particle size distribution measured by 
the OPS was the same as that of the formulation F24 shown in Figure 4.18 (B). The 
SEM image of F25 is given in Figure 4.21 for the reference of its particle 
morphology.  
 
 
(A)  
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(B)  
 
(C)  
Figure 4.20. Sustained drug release in vitro with the 1-μm core-shell particle formulations composed of 
PLGA (Mw: 7K-17K g/mol, LA/GA: 50/50) in the core and shell regions: (A) schematic diagrams of 
formulations F24 and F25, (B) Theophylline (T) release profiles of formulations F24 and F25, (C) 
release profiles of Budesonide (B) and Theophylline (T) from the fixed-combined formulation F25. 
Duplicate testing with N=2.  
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Figure 4.21. The SEM image of particle formulation F25 loaded with both Budesonide and 
Theophylline in the cores and shells of the particles.  
 
4.2.6 Effects of drug-to-polymer ratio of Theophylline on its release rate from 
composite particles co-encapsulating Budesonide and Theophylline  
     As mentioned in previous sections, the drug-to-polymer ratio was set to be 1:10 
throughout the present dissertation work to study the effects of particle filling 
materials, particle shell layer thicknesses and drug loading locations on release 
profiles of core-shell PLGA particles (particle size: 400 nm and 1000 nm) loaded with 
Theophylline and/ or Budesonide. F25 has been concluded to be the 
Budesonide-Theophylline loaded particle formulation capable of providing release 
profiles of both drugs in a most controlled fashion with the drug-to-polymer ratio of 
1:10 throughout this research. However, effects of Theophylline-to-polymer mass 
ratio on the resultant release profiles of Theophylline when it is loaded together with 
 104 
Budesonide in particle core are of interest. For the research purpose, PLGA particles 
(particle size: 400 nm) with the filling materials as PLGA (Mw: 50K-75K g/mol, 
LA/GA: 85/15) in both core and shell of the particles were generated. Both 
Budesonide and Theophylline were loaded in the core regions of the drug carriers 
with the ES process parameters listed in Table 4.8. The Theophylline-to-PLGA mass 
ratios of 1:10 (i.e., F17) and 1:20 (i.e., F26) were tested while the 
Budesonide-to-PLGA mass ratio was fixed at 1:10 for both formulations F17 and F26. 
The resultant release profiles of Budesonide and Theophylline are shown in Figure 
4.22. Higher Theophylline release rate of F17 than F26 was observed because greater 
concentration difference of Theophylline inside and outside the polymer matrix was 
established in the case of formulation F17 for drug diffusion. On the other hand, 
Budesonide drug release rates of F17 and F26 were similar because the concentration 
difference of Budesonide in the polymer matrix and in the surrounding release media 
at the beginning of the diffusion process was identical for both particle formulations. 
According to the discussions in previous sections, PLGA (Mw: 50,000-75,000 g/mol, 
LA/GA: 85/15) is a porous polymeric filler with greater surface porosity and pore size. 
Due to the lower aqueous solubility of the highly hydrophobic drug compounds and 
the greater affinity between such drug compounds and the PLGA materials with 
higher lactic-to-glycolic ratios, the release rates of Budesonide from formulations F17 
and F26 were both slow even though both formulations were less than 500 nm in 
diameter and composed of a PLGA material with high surface porosity and large pore 
size, which were the factors favorable to infusion of the release media. However, it 
was surprising that the release rate of core-loaded Theophylline could be decreased by 
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employing a lower Theophylline-to-PLGA ratio in the nano-particulate formulations. 
The finding suggests that the loading dose of the hydrophilic pharmacological agents 
is also crucial for the extended release combination therapy with PLGA particulate 
drug carriers.  
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(A)  
 
(B)  
Figure 4.22. Release profiles of (A) Budesonide and (B) Theophylline from the 400-nm PLGA particles 
(core and shell: Mw 50K-75 K g/mol, LA/GA: 85/15) loaded with both Budesonide (B) 
(drug-to-polymer mass ratio at 1:10 for F17 and F26) and Theophylline (T) (drug-to-polymer mass 
ratio at 1:10 and 1:20 for F17 and F26, respectively) in the cores of the particles. Duplicate testing with 
N=2.  
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4.3 Summary  
     In this part of dissertation work, Theophylline and/ or Budesonide were loaded 
in core-shell composite PLGA particles with different drug loading configurations. 
Drug-loaded particles with the sizes of 400 nm and 1 μm were generated via the 
coaxial dual capillary electrospray (ES) technique. Various PLGA materials, i.e., 
PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 50/50), PLGA (Mw: 24,000-38,000 g/mol, 
LA/GA: 50/50), PLGA (Mw: 54,000-69,000 g/mol, LA/GA: 50/50) and PLGA (Mw: 
50,000-75,000 g/mol, LA/GA: 85/15) were used as the polymer fillers. The 
investigation was begun from release profile studies for 400-nm particles loaded with 
both Budesonide and Theophylline in different loading configurations (i.e., core: 
Budesonide and Theophylline; core: Budesonide, shell: Theophylline; core: 
Theophylline, shell: Budesonide). The results demonstrated that release rate of the 
core-loaded active ingredient was accelerated due to the void spaces left behind by the 
active ingredient loaded in the shell. Although the drug release rate was affected by 
the drug loading locations along with the void spaces left behind by the shell-loaded 
drug molecules, such a theory could not comprehensively explain the reasons behind 
the differences of release profiles of Budesonide and Theophylline from formulations 
F11-F19. Via the release profile characterizations of the core-loaded Theophylline 
from 400-nm particles (i.e., formulations F20, F22 and F23) composed of PLGA (Mw: 
7,000-17,000 g/mol, LA/GA: 50/50), PLGA (Mw: 24,000-38,000 g/mol, LA/GA: 
50/50) and PLGA (Mw: 50,000-75,000 g/mol, LA/GA: 85/15), the PLGA with lower 
molecular weight was confirmed to be effectively slowing down the release rate of 
Theophylline, achieving a 35% decrease in drug release within the first hour of the 
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2-day release testing according to release profiles of F20 and F22. The finding was 
attributed to the greater surface porosity and larger pore sizes of particles composed of 
PLGA materials with higher molecular weights, which was confirmed by the results 
of BET surface area analysis. The further decrease of Theophylline drug release rate 
was realized by loading Theophylline in core of the thick-shell particles (particle size: 
1 μm) composed of PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 50/50). The presence 
of Budesonide co-encapsulated with Theophylline in the core of the thick-shell PLGA 
particles did not influence the release rate of Theophylline. According to the literature 
reviews, this is a unique research providing effective strategies for extended release of 
Theophylline, a highly hydrophilic compound, from PLGA particulate drug carriers 
with the diameters no greater than 1 μm. No chemical reactions, such as polymer 
cross-linking during the drug encapsulation process or surface modification on 
particulate drug carriers, were involved in our methodology, suggesting its simplicity 
for simultaneous encapsulation of a highly hydrophilic agent and a highly 
hydrophobic agent for extended drug release as a small-molecule combination therapy. 
Formulation F25 could be promising for prevention and treatment of symptoms and 
blockage of airways caused by asthma with the slowly released combination of 
Budesonide and Theophylline. The delivery of Budesonide to the alveolar region with 
the 1-μm PLGA particle formulations can also minimize the immuno suppression that 
is usually resulted from deposition of steroid pharmaceutical aerosols at the upper 
airways for treating asthma.  
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In vitro Drug Release of Small and 
Large-molecule Therapies from  
Core-shell Type ES PLGA Particles 
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5.1 Experiment and Conditions of Core-shell type ES PLGA Nanoparticles 
Generated via a Coaxial Dual Capillary Nozzle  
     Multiple drugs can induce synergistic therapeutic effects to achieve better 
biological outcomes. Combination therapy with multiple drugs administrated has 
become an important treatment modality in many disease categories, such as cancer, 
cardiovascular disease and infectious disease [Center for Drug Evaluation and 
Research, 2013].  
     Cancer arises from a loss of normal cellular growth control, which is caused by 
either uncontrolled cell growth or loss of a cell’s ability to undergo apoptosis. The 
disrupted balance of cell growth and cell death leads to uncontrolled cell proliferation 
and eventually forms a tumor. Tumors which tend to invade nearby tissues, enter 
blood streams and metastasize to different sites of the human body are malignant 
tumors, also known as “cancer.” With defense mechanisms against medicine, such as 
over expression of drug efflux pumps, enhancement of self-repairing ability, increase 
of drug metabolism, and expression of altered drug targets, the combination cancer 
therapy targeting multiple pathologic processes is considered the future for treatment 
of cancer for its intrinsic heterogeneous complexity [Cao et al., 2014]. Since the 
administration time, dose and sequence of different drugs are crucial to achieve 
greatest efficacy and tolerable toxicity to cancer patients, sequential drug release in a 
controlled fashion is thus important to combination cancer therapy [Yanping et al., 
2017; Lee and Nan, 2012].  
     Micro- and nano-particles with multi-layered structures have attracted many 
people’s attention for their capabilities of sequentially-extended drug release of more 
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than one active ingredient form the drug carriers [Lee et al., 2011]. Hybrid polymeric 
micelles with the core and envelope structure have been employed to co-encapsulate a 
conventional small-molecule chemotherapeutic agent Doxorubicin (Dox) and a 
small-molecule anti-angiogenesis agent Combretastatin (Com). Rapid release of 
Combretastatin (Com) loaded within the lipid envelope vascular collapse. The 
resultant intra-tumoral trapped nanoparticles endowed the drug carriers with longer 
duration for the subsequent slow release of the Doxorubicin (Dox) to kill tumor cells 
by inducing their apoptosis [Sengupta et al., 2005]. The anticancer effectiveness was 
reported to be significantly superior to physical mixtures of the two drugs or even the 
liposomal drug formulations. Inspired by the finding, the co-encapsulation of a 
conventional small-molecule chemotherapeutic agent and Bovine Serum Albumin 
(BSA, as a model drug of the monoclonal antibodies used for inhibition of the tumor 
angiogenesis) with the ES core-shell PLGA composite particles was conducted to 
investigate the resultant drug release profiles for their potential applications of 
sequential drug release against cancer. Molecular structure and selective 
physicochemical properties of Paclitaxel (PTX) and Bovine Serum Albumin (BSA) 
are summarized in Figure 5.1 [HUO et al., 2015; Drug Bank Website].  
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Figure 5.1. Molecular structures and selective physiological properties of Paclitaxel and Bovine Serum 
Albumin.  
 
     In chapter 5, PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 50/50) was selected as 
the particle filling material for its excellent capability for extended release of the 
hydrophilic model drug (i.e, Theophylline) according to the results of our previous 
investigation in Chapter 4. PLGA particles with overall sizes ranging from the 
diameters of 400 nm and 880-1150 nm were utilized to encapsulate Bovine Serum 
Albumin and/ or Paclitaxel to study their in vitro drug release profiles. Process 
parameters of the coaxial dual capillary electrospray (ES) to generate the tested 
particle formulations are summarized in Table 5.1-5.3. Due to the lower solubility of 
BSA and PTX in Acetonitrile, the volumetric ratio of Acetonitrile-to-DMSO in the 
spray solvent mixture used in Chapter 5 was lowered from 75:25 to 50:50 in order to 
dissolve PTX. The co-solvent method, i.e., the micro-emulsion of BSA aqueous 
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solution in the polymer solution, was utilized for the encapsulation of BSA in ES 
core-shell particles. The BSA-to-PLGA ratio was set to be 1:50 for the highest BSA 
concentration to be encapsulated into PLGA particles and to be detectable by an 
appropriate protein assay. Accordingly, the PTX-to-PLGA ratio was set to be 2:10 in 
order to shorten the ES process time to minimize the extent of emulsion phase 
separation while PTX was still detectable by HPLC.  
 
 
 
 
 
 
 
 
 
 
 
Table 5.1. Process parameters of the coaxial dual capillary ES for the generation of the core-shell 
PLGA (Mw: 7K-17K g/mol, LA/GA: 50/50) composite particles (particle size: 1 μm) singly 
encapsulating Paclitaxel (PTX) or Bovine Serum Albumin (BSA) in the cores of the particles.  
 
Acetonitrile/DMSO 
(50/50)
Acetonitrile/DMSO 
(50/50)
Spray solvent mixture
8.08.0Tip-to-collector (TTC) distance (cm)
--BSA:PLGA mass ratio
--PTX:PLGA mass ratio
154.64154.64PLGA conc. (mg/ml)
7K-17K; 50/507K-17K; 50/50PLGA (Mw; LA/GA)
2.52.5Feeding flowrate (μl/min)
3030Electric conductivity (μS/cm)
Outer 
solution
1:50-BSA:PLGA mass ratio
-1:5PTX:PLGA mass ratio
2525PLGA conc. (mg/ml)
7K-17K; 50/507K-17K; 50/50PLGA (Mw; LA/GA)
0.50.5Feeding flowrate (μl/min)
3030Electric conductivity (μS/cm)
Inner 
solution
F28F27Formulation ID
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Table 5.2. Process parameters of the coaxial dual capillary ES for the generation of PLGA (Mw: 
7K-17K g/mol, LA/GA: 50/50) composite particles with different shell layer thicknesses to encapsulate 
Bovine Serum Albumin (BSA) in the cores of the particles.  
 
 
 
 
 
 
 
 
 
 
Acetonitrile/DMSO 
(50/50)
Acetonitrile/DMSO 
(50/50)
Acetonitrile/DMSO 
(50/50)
Spray solvent mixture
8.08.08.0Tip-to-collector (TTC) distance (cm)
---BSA:PLGA mass ratio
---PTX:PLGA mass ratio
-20154.64PLGA conc. (mg/ml)
-7K-17K; 50/507K-17K; 50/50PLGA (Mw; LA/GA)
2.52.52.5Feeding flowrate (μl/min)
303030Electric conductivity (μS/cm)
Outer 
solution
1:501:501:50BSA:PLGA mass ratio
---PTX:PLGA mass ratio
252525PLGA conc. (mg/ml)
7K-17K; 50/507K-17K; 50/507K-17K; 50/50PLGA (Mw; LA/GA)
0.50.50.5Feeding flowrate (μl/min)
303030Electric conductivity (μS/cm)
Inner 
solution
F30F29F28Formulation ID
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Table 5.3. Process parameters of the coaxial dual capillary ES for the generation of the core-shell type 
PLGA (Mw: 7K-17K g/mol, LA/GA: 50/50) composite particles (particle size: 430 nm) loaded with 
Bovine Serum Albumin (BSA) and/ or Paclitaxel (PTX) (F29: Core loaded with BSA; F31: Core 
loaded with BSA and PTX; F32: Core loaded with PTX, shell loaded with BSA).  
 
5.2 Release Profile Studies for PLGA Particles Loaded with One Single Agent  
     It is essential to learn drug release behaviors of an active ingredient from a 
single dosage formulation before studying its release kinetics when it is 
co-encapsulated with the other active ingredient within a single dosage formulation. 
Hence, PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 50/50) particles (particle size: 1 μm) 
loaded with either Bovine Serum Albumin (BSA) or Paclitaxel (PTX) were generated 
via process parameters of the coaxial dual capillary ES listed in Table 5.1 for this 
purpose. The schematic diagrams of the as-produced particle formulations are shown 
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in Figure 5.2. According to the release profile of PTX shown in Figure 5.3 (A), less 
than 40% of the loaded drug was released within the first 8 hours of the 2-day release 
testing, which may be attributed to the hydrophobicity of PTX. The highly 
hydrophobic property of PTX led to slow drug dissolution and therefore slow rate of 
diffusion for drug release through the particles with thick shell layers. On the other 
hand, release rate of BSA, according to Figure 5.3 (B), was only slightly higher than 
that of PTX even though the aqueous solubility of BSA is much larger than that of 
PTX. The diffusion coefficient of BSA is significantly smaller than that of PTX. 
Therefore, the resultant release rate of BSA was not greatly higher than that of PTX 
and could be well controlled by the 1-μm core-shell particles composed of PLGA with 
lower surface porosity and smaller pore size, i.e., the PLGA (Mw: 7,000-17,000 g/mol, 
LA/GA: 50/50). The above findings conclude that extended release of both drug 
compounds can be realized by the ES core-shell PLGA particles with a drug 
individually loaded in core.  
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Figure 5.2. Schematic diagrams of drug-loaded ES core-shell PLGA (Mw: 7K-17K, LA/GA: 50/50) 
composite particle formulations (particle size: 1 μm) loaded with Paclitaxel (P) or Bovine Serum 
Albumin (BSA) in core of the particles.  
 
 
(A)  
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(B)  
Figure 5.3. In vitro release profiles of (A) Paclitaxel (P) and (B) Bovine Serum Albumin (BSA) from 
the cores of the 1-μm core-shell PLGA (Mw: 7K-17K g/mol, LA/GA: 50/50) particles with thick shell 
layers.  
 
5.3 Effects of Particle Shell Layer Thickness on BSA Drug Release  
     The effectiveness of particle shell thickness on the extended release of 
hydrophilic small-molecule pharmacologic agent has been demonstrated by 
investigating release profiles of Theophylline from core-shell PLGA (Mw: 
7,000-17,000 g/mol, LA/GA: 50/50) particles (particle size: 400 nm and 1 μm) loaded 
with Theophylline in particle core. Herein, the effect of particle shell thickness on 
release behaviors of the core-loaded BSA was also investigated. PLGA particles 
without shell layers and PLGA particles with shell layers but different in their 
thicknesses were generated via process parameters of the coaxial dual capillary ES 
technique listed in Table 5.2. PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 50/50) was 
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the particle filler for its lower surface porosity and smaller pore size. Schematic 
diagrams of the prepared particle formulations (i.e., F28-F30) and the resultant BSA 
release profiles are given in Figure 5.4 (A) and (B), respectively. The BSA release 
profiles from PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 50/50) particles with 
different shell layer thicknesses evidences that the release rate of core-loaded BSA 
was significantly decreased by gradually increasing the shell thickness of the particles. 
The differences of BSA release profiles between formulations F28, F29 and F30 were 
attributed to the slower permeation of surrounding release media through particle 
shell and longer distance for drug diffusion for the particle formulations with greater 
shell layer thicknesses. Considering the promise of sequential drug release in cancer 
therapy, we focused on the in vitro release behaviors of BSA and PTX from 400-nm 
core-shell PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 50/50) particles for their 
potential biopharmaceutical applications in the following sections in this chapter.  
 
 
(A)  
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(B)  
Figure 5.4. Evaluation of the effect of particle shell layer thickness on release profiles of core-loaded 
BSA from PLGA (Mw: 7K-17K g/mol, LA/GA: 50/50) particles with various shell thicknesses: (A) 
schematic diagrams of tested particle formulations with different shell thicknesses, (B) in vitro BSA 
release profiles from particle formulations listed in (A).  
 
5.4 Effects of Drug Combination on Release Behaviors  
     Similar to the research in extended release of fixed-combined Budesonide (the 
hydrophobic small-molecule model drug) and Theophylline (the hydrophilic 
small-molecule model drug) with PLGA particulate drug carriers, release profiles of 
core-loaded Bovine Serum Albumin (BSA, a model drug of protein biologics for the 
inhibition of tumor angiogenesis) were also investigated with or without Paclitaxel 
loaded together in the particle cores. According to BSA release profiles of the tested 
formulations F28, F29 and F30 given in Figure 5.4 (B) with different shell layer 
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thickness and accordingly different particle diameters, the 400-nm core-shell PLGA 
(Mw: 7,000-17,000 g/mol, LA/GA: 50/50) particles were chosen to be the drug 
carriers used for the relatively faster BSA release rate of F29 (around 40% of the 
loaded BSA released within the first 4 hours of the release testing) than F28 and the 
better sustained release profile for BSA from F29 than F30. Furthermore, the 400-nm 
core-shell PLGA drug carriers are also more suitable for cancer therapy compared to 
the 1-μm PLGA particles for their smaller particle sizes to accumulate in malignant 
tumors. By using the ES process parameters listed in Table 5.3, the 400-nm core-shell 
PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 50/50) particle formulation loaded with 
both Paclitaxel together with Bovine Serum Albumin (i.e., formulation F31) was 
produced as the schematic diagram shown in Figure 5.5. To study the effects of 
co-encapsulated Paclitaxel on release of Bovine Serum Albumin, the resultant Bovine 
Serum Albumin release profile of formulation F31 was compared with that of 
formulation F29 and shown in Figure 5.6. Faster BSA release rate from F31 was 
observed, implying that the release rate of Bovine Serum Albumin was enhanced by 
the presence of Paclitaxel when both drugs were loaded in the core of 400-nm PLGA 
(Mw: 7,000-17,000 g/mol, LA/GA: 50/50) particles. The finding could be associated 
with the void spaces in particle cores left behind after the release of Paclitaxel. 
Compared to the effects of Budesonide (the hydrophobic small-molecule model drug) 
on the release behaviors of Theophylline (the hydrophilic small-molecule model drug) 
when both drugs were loaded in particle core (Section 4.2.5), release of the 
hydrophobic small-molecule model drugs, i.e., Paclitaxel, in this case left behind 
pores with larger sizes due to the larger molecular weight of Paclitaxel than 
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Budesonide. The release rate of Bovine Serum Albumin, the hydrophilic 
large-molecule model drug, was slower than that of Theophylline (the hydrophilic 
small-molecule model drug in Chapter 4). In the end, the void spaces left behind by 
the released Paclitaxel induced more rapid release media infusion, which accelerated 
the release rate of the co-encapsulated Bovine Serum Albumin in particle cores. 
Around 50% of the loaded BSA was released within the first 4 hours of the release 
testing suggests that F31 could be used for sequential release of Bovine Serum 
Albumin and Paclitaxel, which will be further discussed in the following sections.  
 
 
 
Figure 5.5. Schematic diagrams of the 400-nm core-shell PLGA (Mw: 7K-17K g/mol, LA/GA: 50/50) 
particle formulations loaded with Bovine Serum Albumin (BSA) and/ or Paclitaxel (PTX) in various 
tested drug loading configurations.  
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Figure 5.6. In vitro Bovine Serum Albumin (BSA) release profiles from the 400-nm core-shell PLGA 
(Mw: 7K-17K g/mol, LA/GA: 50/50) particle formulations loaded with Bovine Serum Albumin (BSA) 
and/ or Paclitaxel (PTX) in particle cores.  
 
5.5 Sequential Drug Release of Fixed-dose Combination of BSA and PTX from 
PLGA Particles  
     To investigate the sequential release of Bovine Serum Albumin (BSA) and 
Paclitaxel (PTX) from the 400-nm core-shell PLGA (Mw: 7,000-17,000 g/mol, 
LA/GA: 50/50) particles, two particle formulations with designated drug loading 
configurations, i.e., F31 and F32 illustrated in Figure 5.5 , were generated via the ES 
process parameters listed in Table 5.3. The resultant PTX and BSA release profiles 
displayed in Figure 5.7 depict very limited variance in release behaviors of PTX and 
BSA between formulations F31 and F32. For formulation F32, release of shell-loaded 
Bovine Serum Albumin should create large void spaces that further improved the 
infusion of the release media to the particle core. However, the extent of the enhanced 
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release media infusion was insufficient to rapidly dissolve the core-loaded Paclitaxel 
since its aqueous solubility is extremely low (3x10-4 mg/ml). Therefore, the Paclitaxel 
release rate from F32 was slightly higher than that from F31 without too much 
difference. On the other hand, release rate of BSA was not appreciably increased by 
loading BSA in the particle shell (i.e., F32) as expected. The shell layer thickness (90 
nm) of the 400-nm core-shell PLGA drug carrier was not thick enough to provide a 
barrier to the infusion of the release media and the diffusion of BSA. As a result, BSA 
release rates of F31 and F32 were almost identical without too much difference.  
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(A) 
 
 
(B)  
Figure 5.7. Release profiles of (A) Paclitaxel (P) and (B) Bovine Serum Albumin (BSA) from the 
400-nm core-shell PLGA (Mw: 7K-17K g/mol, LA/GA: 50/50) composite particles loaded with 
Paclitaxel and Bovine Serum Albumin in tested drug loading configurations (F31: Core loaded with 
Paclitaxel and Bovine Serum Albumin; F32: Core loaded with Paclitaxel, shell loaded with Bovine 
Serum Albumin).  
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The overall release profiles of PTX and BSA from formulations F31 and F32 
are given in Figure 5.8, concluding that both particle formulations were capable of 
sequentially releasing BSA first and then the PTX. The relatively faster release rate of 
BSA suggested that both formulations are able to more rapidly release monoclonal 
antibodies in the first place for the inhibition of tumor angiogenesis. The slower, but 
continuous, release of PTX unremittingly inhibits the cell division process for greater 
anti-cancer outcomes. As a conclusion, both formulations F31 and F32 could be 
promising for cancer therapy by sequential drug release.  
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(A)  
 
(B)  
Figure 5.8. Release profiles of Paclitaxel (P) and Bovine Serum Albumin (BSA) from the 400-nm 
core-shell PLGA (Mw: 7K-17K g/mol, LA/GA: 50/50) composite particles loaded with Paclitaxel and 
Bovine Serum Albumin in tested drug loading configurations: (A) formulation F31, (B) formulation 
F32.  
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5.6 Summary  
     In this part of dissertation work, PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 
50/50) was selected as the particle filling material for its lower porosity and smaller 
pore sizes according to the results previously addressed in Chapter 4. Core-shell 
particles with the sizes of 400 nm and 1 μm were produced by the coaxial dual 
capillary ES to encapsulate Bovine Serum Albumin (BSA, the hydrophilic model drug 
of monoclonal antibodies) and/ or Paclitaxel, (PTX, the hydrophobic small-molecule 
chemotherapeutic agent). Release profiles of PTX and BSA singly loaded in the core 
of the 1-μm PLGA particles demonstrated that both drugs can be slowly released from 
the particulate core-shell particles used in this part of research. Particles with different 
shell layer thicknesses were also generated with BSA loaded in the core to study the 
effect of shell thickness on release behaviors of BSA. Results confirmed that release 
rate of BSA was associated with the particle shell thickness. Thicker particle shell 
layer decreased the release rate of BSA by prolonging the time for infusion of the 
release media to particle cores and the distance for the diffusion of BSA molecules to 
be released to the release media. Considering the BSA release rate of F29, the 400-nm 
core-shell PLGA particles were chosen as the drug carrier to study whether the BSA 
release behavior would be influenced by the presence of PTX in the same location 
within the particles. The increased release rate of core-loaded BSA was reported when 
PTX was co-encapsulated with BSA in core of the particles. The reason behind the 
observation was explained by greater infusion of the release media caused by the void 
spaces left behind by the release of PTX. Due to the appreciably larger molecule 
weight of BSA than small-molecule hydrophilic agents, greater infusion of the release 
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media had chances to accelerate the dissolution process for drug diffusion. Though the 
formulation F31 has demonstrated its capability of sequential drug release of BSA and 
PTX already, release profiles of the formulation F32 were further investigated to learn 
whether the release rate of BSA could be further enhanced by loading BSA in the 
shell region of the 400-nm core-shell particles. The results indicated that both release 
rates of PTX and BSA was not accelerated by loading BSA in particle shell, which 
was attributed to the extreme hydrophobicity of PTX and the fast dissolution of BSA. 
Through this part of the study, it was evidenced that the release rate of BSA can be 
tailored by the particle shell thickness, and the sequential release of BSA and PTX can 
be realized by the core-shell PLGA nanoparticles produced by the dual capillary ES 
technique as a potential pharmaceutical particle formulations for treating Metastatic 
Breast Cancer.  
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6.1 Overall Summary  
     Effective drug concentration at the site of action for a sufficient duration is 
crucial in order to provide greater biological outcomes. Such a concept can be realized 
through the application of extended release formulations to drug delivery systems. 
Furthermore, the extended release formulations are also favorable to enhance the 
safety, the convenience and the compliance of the drug products for patients. Due to 
the capabilities of drug combinations to direct at multiple therapeutic targets for 
improved biological outcomes, the application of combination therapy has become an 
important therapeutic approach in many disease settings. Fixed-dose combinations 
(FDCs) offer an alternative to the patients requiring multiple therapies to manage their 
diseases for the simplified medication regimen and the improved patient compliance. 
Similar to the conventional monotherapy, maintaining blood levels of all released 
active ingredients from pharmaceutical dosages to be within the therapeutic window 
for longer period of time is important to assure the greatest efficacy and the 
minimized side effects to patients.  
     PLGA is a biodegradable polymeric material that has been approved by U.S. 
FDA and EMA and widely applied to extended drug release for its excellent 
biocompatibility and innocuous degradation products for minimal safety concerns. 
For the capabilities of fabricating PLGA particles with a myriad of filling material 
compositions, drug loading configurations, internal structures and sizes, the coaxial 
dual capillary electrospray (ES) technique was chosen to generate drug-loaded PLGA 
core-shell particles (particle size: 400 nm and 1 μm in diameter) to study factors 
influencing the resultant drug release behaviors of the loaded hydrophilic and/ or 
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hydrophobic model drug compounds. Key factors were also identified for most 
efficiently slowing down release rates of the hydrophilic model drugs. Drug release 
behaviors of all tested particle formulations were learned from their in vitro drug 
release profiles characterized by HPLC and the NanoOrange Protein Assay for 
small-molecule model drugs (Budesonide, Theophylline and Paclitaxel) and Bovine 
Serum Albumin (BSA, the model drug of monoclonal antibodies), respectively. Drug 
release testing was performed in 10 ml PBS (0.02 M, pH 7.4) as the release media at 
36.5 oC. In vitro drug release studies of matrix-type PLGA (Mw: 7,000-17,000 g/mol, 
LA/GA: 50/50) nanoparticle formulations (particle size: 70-80 nm, produced by the 
single capillary ES) loaded with Budesonide at different Budesonide-to-PLGA ratios 
were performed to determine the drug-to-polymer ratio to be 1:10 for all tested 
particle formulations in Chapter 3 and Chapter 4 (except for formulations F17 and 
F26). Differently, the PTX-to-PLGA and the BSA-to-PLGA mass ratios were set at 
1:5 and 1:50, respectively, for all tested particle formulations in Chapter 5 considering 
the aqueous solubility of BSA and the phase separation issue happening during the ES 
process. The major findings of the present dissertation work are summarized as 
below:  
Part 1 In vitro release profile studies on Theophylline (the hydrophilic small-molecule 
model drug) and/ or Budesonide (the hydrophobic small-molecule model drug) from 
core-shell PLGA particles:  
1. According to Theophylline release profiles of formulations F20 and F21, the 
release rate of Theophylline from the 400-nm core-shell PLGA (Mw: 
50,000-75,000 g/mol, LA/GA: 85/15) particle formulations loaded with 
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Theophylline in the core can be increased by additionally loading Theophylline in 
particle shell. The finding suggests that the drug-loaded core-shell PLGA 
nanoparticles could be applied to repeat-action formulations to maintain the blood 
level of an active pharmaceutical ingredient with a short half-life within its 
therapeutic window for longer period of time.  
2. The molecular weight and the lactic-to-glycolic ratio of PLGA are crucial for the 
sustained release of Theophylline. It is evidenced that the release rate of the 
core-loaded Theophylline is lower when Theophylline is loaded in the cores of the 
400-nm particles composed of PLGA with a lower molecular weight and a lower 
LA/GA ratio because of the lower porosity and the smaller pore sizes of the 
particle filling material.  
3. Release behaviors of Budesonide and Theophylline from core-shell PLGA 
particles co-encapsulating both drugs cannot be explained simply by the drug 
loading locations within the particles. Void spaces in the particle shell layers left 
behind by the release of the shell-loaded drug molecules can induce greater 
infusion of the release media and therefore accelerate the release rate of the 
core-loaded drug molecules.  
4. The particle shell layer thickness is essential to sustained release of Theophylline. 
By using PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 50/50) as the particle filler, 
the Theophylline release rate can be significantly decreased by core-shell particles 
with thicker shell layers.  
5. The release rate of the core-loaded Theophylline from the 1-μm PLGA (Mw: 
7,000-17,000 g/mol, LA/GA: 50/50) particles is not affected by the presence of 
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Budesonide loaded in particle cores. As a result, the 1-μm drug-loaded PLGA 
particle formulations co-encapsulating Budesonide and Theophylline in the cores 
are capable of slowly releasing both loaded drugs as a promising fixed-dose 
combination extended release formulation.  
 
Part 2 In vitro release profile studies on Bovine Serum Albumin (the hydrophilic 
large-molecule model drug) and/ or Paclitaxel (the hydrophobic small-molecule 
model drug) from core-shell PLGA particles:  
1. Sustained release of Bovine Serum Albumin (BSA) can be realized by the 
encapsulation of BSA in the cores of PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 
50/50) particles. The BSA release rate is also affected by the thickness of the 
particle shell layers. It is reported that the release rate of BSA is lower from the 
core-shell PLGA particles with greater shell thicknesses.  
2. The presence of Paclitaxel (PTX) in the particle core accelerates the release rate of 
the core-loaded BSA when both compounds are co-encapsulated in the cores of 
the 400-nm PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 50/50) particles. The 
finding implies the potential applications of the as-produced PTX-BSA loaded 
particle formulations to sequential release of a protein and a small-molecule 
conventional chemotherapeutic compound for combination cancer treatment.  
3. The loading locations of BSA do not impact the performance of sequential drug 
release of the PTX-BSA loaded core-shell PLGA (Mw: 7,000-17,000 g/mol, 
LA/GA: 50/50) particles (particle size: 400 nm) when PTX is loaded in particle 
cores. The observation may be associated with the insufficient shell thickness and 
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the extremely low aqueous solubility of PTX.  
 
6.2 Future Work 
     The present dissertation work is an exploratory study demonstrating one of the 
possible strategies for in vitro extended release and/ or sequential release of the 
fixed-dose combinations containing a highly hydrophobic small-molecule agent with 
a highly hydrophilic small-molecule or a hydrophilic large-molecule agent from 
PLGA particles. Due to the therapeutic effectiveness of the selected model drugs, the 
as-produced particle formulations could be potential for therapeutics of inhalation 
diseases and malignant tumors. However, more efforts are needed to study the 
feasibilities of the as-produced drug-loaded PLGA particles for the treatment of the 
aforementioned diseases:  
1. The mixing of core-shell PLGA particles loaded with one drug individually could 
also be a strategy of fixed-dose combination therapy. Relevant particle 
formulation generation tasks and in vitro drug release testing should be conducted 
to study the resultant drug release profiles and their differences from the release 
profiles of core-shell PLGA particles co-encapsulating a hydrophilic and a 
hydrophobic model drug.  
2. Phosphate buffered saline simulates only limited aspects of physiological fluids, 
the pH and the ionic strength. It is well established that drug release in PBS is 
different from that in protein-containing media. Release testing should be further 
performed in media containing proteins at a concentration relevant to the target 
site of actions in the human body. The pH and the osmotic pressure effects should 
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also be studied to confirm extended release of the drug-loaded particles can be 
achieved under the physiological environment of the target tissues.  
3. The incapability of the electrospray (ES) to completely remove the solvents used 
in the process has been addressed in literature. To minimize the safety concerns of 
the residual solvent in the prepared PLGA particles, content of residual solvent 
should be identified before proceeding with the subsequent cell, animal, or even 
human studies.  
4. From the view points of pharmaceutics, controlling drug release rate is meaningful 
when the active pharmaceutical ingredient is stable. That is why the stability of 
the small-molecule and the large-molecule model compounds during the release 
testing should be investigated in order to provide effective therapeutic outcomes 
to patients.  
5. A simple and reliable process for mass production of the drug-loaded particles is 
the prerequisite for their real applications to disease treatment. That is why the 
multi-notched ES nozzle should be utilized to generate drug-loaded core-shell 
PLGA particles with greater mass throughput. The resultant in vitro drug release 
profiles should be studied for the performances of the as-produced PLGA particle 
formulations in extended and sequential drug release.  
6. It is suggested that the cell and/ or animal studies should be conducted with the 
as-produced drug-loaded PLGA particles from this thesis work to further look into 
the safety and efficacy of the extended release and the sequential release 
particulate formulations.  
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